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Pancreatic cancer is a devastating disease that leaves patients with a very poor
prognosis and few therapeutic options. Many of the treatment options available are the
same that have been used for almost 2 decades. There is a dire need for both novel
treatments for this disease as well as novel strategies of treatment. This body of work
will introduce and provide evidence in support of a novel combination therapy for
pancreatic

cancer

treatment,

a

novel

strategy

of

modifying

currently

used

chemotherapeutics for pancreatic cancer therapy, and a novel transgenic preclinical
mouse model of pancreatic cancer. Sabutoclax, an antagonist of the anti-apoptotic Bcl-

xiii

2 proteins, and Minocycline, a commonly used antibiotic, show potent synergy when
used in combination in both pancreatic cancer cells and in multiple immune-deficient
and immune-competent mouse models of pancreatic cancer.

Sabutoclax alone is

capable of inducing cell cycle arrest and apoptosis in cells and its cytotoxicity is
enhanced significantly when combined with Minocycline. This combination results in
the loss of Stat3 activation both in vitro and in vivo, which is essential for its toxicity. It
also inhibits tumor growth and prolongs survival in the KPC transgenic mouse model of
pancreatic cancer. Also presented here are studies that demonstrate efficacy in vivo of
modified versions of Gemcitabine and Paclitaxel. These drugs are linked to a peptide
that shows specificity for the EphA2 receptor, which is overexpressed on the surface of
pancreatic cancer cells and only minimally on normal cells. This peptide results in
increased cellular uptake of drug, as it is bypassing its normal mechanism of entry.
These normal mechanisms are often dysregulated in cancer, leading to decreased
uptake and drug resistance.

The use of these modified drugs show significantly

increased tumor growth inhibition as compared to the parent drug alone. Finally, we
provide data on the characterization of a novel transgenic mouse model of pancreatic
cancer. This model, the Pan Met View (PMV) mouse, combines the commonly used
KPC transgenic mouse model of pancreatic cancer and a mouse that expresses a
Luciferase reporter gene under the control of the cancer-specific promoter, CCN1. Our
data shows that double transgenic PMV mice can now be used to follow primary tumor
and metastasis development in real time by Bioluminescent imaging (BLI) through
disease progression and potentially therapy. This strategy will enhance the use of
genetically engineered mouse models (GEMMS) to study cancer initiation and

xiv

progression with potential to non-invasively monitor therapy. These chapters present
novel and exciting data that have the potential to open multiple avenues of translational
study and result in significant advances in pancreatic cancer therapy.

xv

Chapter 1: Introduction

I.

Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer
that is estimated to result in over 39,000 deaths in the US in 2014 (NCI 2014). It is
currently the fourth most commonly diagnosed cancer and holds a 5-year survival
rate of about 4% (1). This poor prognosis results, in part, from a delayed diagnosis
of the disease. Patients experience few symptoms and those that they may
experience tend to be vague in nature. Abdominal pain, depression, weight loss,
and loss of appetite are all commonly seen, though they are often overlooked until
they become chronic issues. Jaundice can be a symptom of pancreatic head
tumors, which is much more telling of a significant underlying problem. The
consequence of this clinical presentation is that most patients have either locally
advanced or metastatic disease at the time of diagnosis. Risk factors for pancreatic
cancer include a history of smoking, diabetes, chronic pancreatitis, and some
inherited genetic mutations/familial diseases (2).
II.

Pancreatic Cancer Therapy

Unfortunately, treatment options remain minimal for patients diagnosed with this
aggressive disease. Surgical resection is the only potentially curative treatment, but,
due to delayed diagnosis, is only an option for approximately 15% of patients (2).
Because of the anatomical location of the pancreas, even tumors discovered before
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metastatic spread are usually not resectable. Significant involvement of the tumor
with surrounding vital organs and vessels, such as the celiac trunk, superior
mesenteric artery/vein, and the hepatic artery, eliminate its ability to be surgically
removed (2). This tumor involvement, which can often eventually encase organs or
vessels entirely, can often be a primary cause of death in these patients, a result of
the rupture of vessels or impairment of normal function.
Chemotherapy remains the most utilized option for patients with pancreatic
cancer, though outcomes are still poor. Gemcitabine remains the standard of care,
even though it has been almost 2 decades since it was established to have a
prolonged survival benefit as compared to Fluorouracil (3). Despite this, Fluorouracil
is still used in treatment regimens, as well as a number of novel combination
therapies. Folfirinox, a combination of fluorouracil, irinotecan, oxaliplatin, and
leucovorin, has been shown to improve survival in patients with metastatic disease
and is now being evaluated in patients with locally advanced tumors. Additionally,
the combination of Gemcitabine and nab-Paclitaxel (Abraxane) was also recently
approved by the FDA for the treatment of metastatic pancreatic cancer after clinical
trials showed significant survival advantages. These two combination therapies are
now considered standard of care for patients with metastatic disease.

Though

radiotherapy is often incorporated into some treatment regimens and clinical trials,
data regarding its efficacy remains somewhat controversial (2).

III.

Genetics of Pancreatic Cancer

2

The aggressive nature of the cancer and the resulting dismal prognosis for patients
results, in part, from the vast array of molecular changes that occur during the
development of pancreatic adenocarcinoma. Pancreatic tumors are known to be
chemoresistant as well and this resistance to therapy is often due to the many different
genetic changes seen in pancreatic tumors.
The development of a pancreatic adenocarcinoma follows a sequence of
histological changes that turns a normal pancreatic epithelium into an invasive
pancreatic adenocarcinoma. This process has been classified into a series of preinvasive stages referred to as pancreatic intraepithelial neoplasia (PanIN) lesions
(Figure 1). These dysplastic ductal lesions range in number from PanIN I (low-grade
lesion to PanIN 3 (high grade lesion or pancreatic ductal adenocarcinoma in situ).
These progressive histological changes occur as the result of parallel underlying
molecular changes. It is these molecular changes that ultimately result in an invasive
pancreatic adenocarcinoma. It is also important to note that these changes occur at
fairly specific time points throughout this progressive model and in a particular order.
Additionally, not all pancreatic cancers will have the exact same molecular changes,
further contributing to its inherent aggressive and chemoresistant nature. Different
tumors will often have different combinations of genetic mutations, chromosomal losses,
etc. This is why finding therapy to treat pancreatic cancers as a group remains so
difficult. Despite the vast number of potential molecular changes, there are a few that
occur in a large number of pancreatic cancer cases.
A. Major Oncogenes and Tumor Suppressors
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One of the very first changes that occur in a normal pancreatic epithelial cell is the
mutation of K-ras. K-ras is part of the Ras family of proteins that is involved in signal
transduction through the MAPK and PI3K/Akt pathways. K-ras is mutated in over 90%
of pancreatic cancers and primarily responsible for the initial transformation event in
normal cells. This mutation has been seen in codons 12, 13, and 61, with codon 12
being the most frequently seen sight for K-ras mutations (4). This oncogenic, early
event results in constitutive activation of K- ras and is seen in PanIN 1 lesions through
to invasive carcinoma. K- ras mutation is seen in approximately 36% of PanIN-1A
lesions, 44% of PanIN-1B lesions, and 87% of PanIN 2-3 lesions (5). It should also be
noted that pancreatic adenocarcinomas that arise in a patients with chronic pancreatitis
tend to have lower frequencies of K-ras mutations, though the reason is not entirely
clear (4).
In vitro and in vivo studies have confirmed K-ras mutation as an early and
initiating event in the development of PDAC. Mouse models developed that express
mutant K-ras in the pancreas result in the generation of ductal lesions resembling PanIN
lesions (6).

4

Figure 1: Genetic Progression Model of Pancreatic Cancer. Adapted from (7).
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One of the next changes often seen affects the gene encoding p16,
CDKN2A/INK4A. p16 is a cell cycle checkpoint protein and can initiate G1-S phase
arrest. It is a very important protein in normal cell cycle function and is lost in around
90% of pancreatic cancer cases. Though p16 is lost in the majority of PDAC cases, the
mechanism of its loss is not always the same. Possible mechanisms of p16 loss
include homozygous deletion of the CDKN2A/INK4A gene, intragenic mutation plus the
loss of the 2nd allele, and epigenetic silencing through promoter methylation (4). Loss of
p16 is considered a fairly early to intermediate event in the development of PDAC.
Around 30% of PanIN-1A and 1B lesions, 55% of PanIN 2 and 71% of PanIN 3 lesions
show loss of p16 (4). Additionally, as seen with K-ras mutations, the frequency of loss
of this tumor suppressor is decreased in cancer cases resulting from chronic
pancreatitis.
The next big molecular event seen in the progression to PDAC is the inactivation
of the TP53 gene. p53 function is lost in approximately 50-75% of pancreatic
adenocarcinomas and occurs much later in PDAC development, with changes in p53
not usually seen until the stage of a PanIN-3 lesion. It is normally involved in cell cycle
regulation and loss of it results in inappropriate cell cycle progression. It is also thought
to contribute to the overall genomic instability seen in pancreatic cancer. In the majority
of cases, p53 function is lost through intragenic mutation of one allele and loss of the
second.
Another late event that occurs in PDAC development is the loss of the
DPC4/SMAD4/MADH4 gene. The SMAD4 protein is involved in signal transduction
downstream of TGF-β and plays a role in growth inhibition. Loss of this tumor
6

suppressor gene therefore results in uncontrolled proliferation. This gene is lost in 5090% of pancreatic cancers (8). SMAD4 is expressed in lower and intermediate stage
PanIN lesions and lost in 31-41% of PanIN-3 lesions, supporting this as a later
occurring event (4).
These four changes are the most significant and frequent molecular events seen
in the development of pancreatic adenocarcinoma. Animal models developed by
different groups have shown that combinations of K-ras mutations and loss of these
tumor suppressor genes result in the development of a pancreatic adenocarcinoma in
mice that closely resembles human PDAC (9).
B. Stat3
Stat3 is a transcription factor that is a part of a large family of signal transducer
and activator of transcription (STAT) proteins. This family consists of seven proteins
and they each carry six conserved protein domains. These domains consist of a
tetramerization domain, a N-terminal coil-coil domain, a DNA-binding domain, a linker
domain, a SH2 domain, and a C-terminal transactivation domain (10). These domains
play important roles in the normal function of Stat3 and can have clinical implications as
well.
In a normal cell, Stat3 resides predominantly in the cytoplasm. When ligand
binding activates tyrosine receptor kinases, they dimerize and undergo
transphosphorylation. This activates a series of phosphorylation steps that can involve
a variety of different intracellular kinases. These phosphorylations lead to the
recruitment of proteins that are involved in signal transduction pathways. Stat3 is one
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such protein. It gets recruited to the receptor complex via its SH2 domain and then it
becomes phosphorylated (11). Stat3 has a tyrosine residue at position 705 and a
serine residue at position 727, both of which can be phosphorylated. In most cases, it is
a tyrosine kinase involved in this process and, as a result, tyrosine 705 of Stat3 is
usually the phosphorylation site involved in this protein’s activation. While multiple
kinases are able to phosphorylate and subsequently activate Stat3, most times it is the
JAK family of kinases that carry out this job (12).
Once Stat3 is phosphorylated, it forms a dimer with another Stat3 monomer
through the binding of the phosphorylated tyrosine of one monomer to the SH2 domain
of the second. This forms an active Stat3 dimer. This dimer is now able to translocated
into the nucleus, where it function as a transcription factor, binding DNA and regulating
gene expression of its targets (10).
As a transcription factor, Stat3 can regulate the expression of its transcriptional
targets. It is through the regulation of these targets that Stat3 can be responsible for the
cancer supporting phenotype seen when it becomes constitutively active. Many of the
transcriptional targets of Stat3 play pro-survival roles in the cell and, when Stat3
signaling goes unregulated, these targets become active players in cancer
development. Some of these targets are important specifically in pancreatic cancer and
include (but are not limited to) the antiapoptotic members of the Bcl-2 family, Cyclin D1,
and VEGF (13).
Targeting Stat3 in pancreatic cancer has further shown the importance of this
protein in this disease. Yang, et. al. showed that knocking down Stat3 via lentivirus
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mediated RNAi in a pancreatic cancer cell line resulted in decreased cell growth,
decreased expression of VEGF and MMP-2, and decreased invasive abilities in a invitro invasion assay (Yang, G. et. al. 2009). Lewis, et. al. utilized a different approach
by developing oligonucleotides complementary to binding sequences of Stat3. They
showed that these oligos were able to induce apoptosis in a pancreatic cancer cell line
and that they could decrease expression of Stat3 target CD46. CD46 is a protein that
can protect tumor cells from complement-mediated cytotoxicity (Lewis, HD, et. al. 2008).
These two methods target Stat3 expression and activity. Other methods, such
as the development of peptide inhibitors and small molecule inhibitors, take a look at the
activation of the Stat3 monomer and use this process to develop inhibitors. As
mentioned previously, activated Stat3 monomers form dimers via their SH2 protein
domains. It is this dimer that can translocate to the nucleus and carry out its
transcriptional function. A strategy in targeting Stat3 has been to develop inhibitors that
bind to this SH2 domain, prohibiting it from binding to another Stat3 monomer and
forming a functional dimer.
This was first accomplished by Turkson, et. al. This group created the peptide,
PY*LKTK (Y* = a phosphorylated tyrosine), that bound to the SH2 domain of a Stat3
monomer. However, like many firsts, this peptide did not exhibit good efficacy and
required high doses to achieve results (Turkson, J. et. al. 2001). Further derivatives
were developed by multiple groups, but, as with many peptide inhibitors, the polarity of
them and the transient nature of the phosphate groups resulted in problems
(Haftchenary, S. et. al. 2011). Ge, et. al. tried to address this problem by developing an
unnatural amino acid meant to replace the phosphorylated tyrosine. In this amino acid,
9

the phosphate group was replaced by an isoxazole carboxylic acid moiety. The
compound made with this new amino acid, ISS610, was a tripeptide that was shown to
have moderate inhibitory effects against the SH2 domain of Stat3 and improved cell
permeability (Ge, J. et. al. 2010).
Many of the small molecule inhibitors of Stat3 aim to function in the same way as
the peptide inhibitors, by targeting the SH2 domain of Stat3 and preventing
dimerization. However, small molecule inhibitors often have much greater efficacy than
peptide inhibitors due to their more advantageous physiological properties. For
example, small molecule inhibitors are able to rapidly diffuse through cell membranes, a
property not exhibited by peptide inhibitors. Though there have been many Stat3 small
molecule inhibitors developed, those discussed here will focus on two that have been
studied in the context of pancreatic cancer, LLL12 and Cucurbitacin.
LLL12 was developed by Lin, et. al. via a structural based approach. It has been
shown to bind directly to phosphorylated tyrosine 705 and exert a variety of inhibitory
effects on cancer, but not on normal, cells. In pancreatic cell lines, LLL12 was shown to
reduce Stat3 DNA binding, induce apoptosis, and decrease mRNA and protein
expression of Stat3 targets CyclinD1, Survivin, and Bcl-2 family anti-apoptotic proteins.
Additionally, it showed synergy with Gemcitabine, the current first line treatment for
pancreatic cancer (Lin, L. et. al. 2010).
Cucurbitacin, unlike LLL12 and other Stat3 small molecule inhibitors, functions by
targeting the JAK family of kinases. Inhibition of these proteins blocks Stat3 activation
at the level of the receptor complex (Jing, N. et. al. 2005). Zhang, M. et. al. examined
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the effect of Cucurbitacin B in pancreatic cancer. This group found that in addition to
decreasing Stat3 activation, this compound inhibited pancreatic cancer cell growth,
induced apoptosis, increased p21 levels, and decreased Stat3 targets Bcl-2 and
survivin (Zhang, M. et. al. 2010).

C. Other Genetic Alterations
As mentioned earlier, the aggressive nature of this cancer is due to the vast
number of molecular events that occur in its development. In addition to the major
genetic changes seen, there are many other alterations that occur during the
development of this cancer. Examples of these include overexpression of the HER2/NEU/ERBB2 gene, mutation of the BRCA2 gene and upregulation of the proteins
Cyclin D1 and COX-2.
Overexpression of the HER-2/NEU gene is something that sometimes occurs as
an early event in the development of PDAC. Reports vary as to what percentage of
pancreatic cancers exhibit overexpression and range from 7-82% (14). Overexpression
and therefore activation of this oncogene leads to constant proliferative signals through
a multitude of pathways.
Another late event in PDAC development is mutation of the BRCA2 gene.
BRCA2 is involved in DNA damage repair in cells, and loss of the normal function of the
associated protein results in accumulation of DNA damage in cells. BRCA2 is mostly
associated with inherited pancreatic cancer cases. Germline BRCA2 mutations
predispose patients to pancreatic cancer, increasing their lifetime risk by 5-10% (15).
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Despite this, there are cases of sporadic pancreatic cancer with BRCA2 mutations.
Around 7-10% of pancreatic cancer cases are found to have a germline BRCA2
mutation, some of which were thought to be sporadic (4).
Cyclin D1 is another protein often overexpressed in pancreatic cancer. Cyclin D1
functions normally as part of the cell cycle in conjunction with cyclin-dependent kinases
4 and 6. Together, these proteins inactivate the retinoblastoma gene (Rb), an inhibitor
of cell cycle progression, and encourage the cell cycle to proceed. Overexpression of
CyclinD1, therefore, accelerates cell cycle progression. Nuclear overexpression is seen
in around 33% of PanIN-2 lesions, over 50% of PanIN-3 lesions, and in between 6080% of invasive PDAC (4). Importantly, cyclin D1 overexpression has been correlated
with decreased survival in patients with pancreatic ductal adenocarcinoma (16).
Well known for its role in inflammation, Cox-2 also can be involved in the
development of cancer. One study found Cox-2 to be overexpressed by
immunohistochemistry in between 69 and 81% of pancreatic tumors (17). It is also
increasingly expressed as lesion progresses from a PanIN-1 lesion to a PanIN-3 lesion
(4).
Changes in some of genes/proteins already discussed can lead to activation of
not only the individual protein, but of whole pathways as well. K-ras is an example of
this. Interestingly, activation of some other pathways seen in pancreatic cancer
includes a few normally involved in embryological signaling. The Hedgehog and Notch
signaling pathways are actively involved in embryological development of different
organs and are usually turned off in adult tissues. However, in pancreatic cancer, there
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is evidence of activation of the components of these pathways, as well as some of their
targets, like the Hes1 gene of the Notch pathway (4). As their embryological function
involved regulation of cell differentiation, this activation may play a role in the abnormal
differentiation and transformation seen in invasive pancreatic cancer (18).
As in many types of cancer, there is a large degree of genomic instability seen
both throughout the PanIN stages and in pancreatic adenocarcinoma. The result is
many chromosomal abnormalities, both numerical and structural. Loss of chromosomal
material can lead to some of the changes discussed above, such as loss of the
DPC4/SMAD4/MADH4 gene, which is located on frequently lost locus 18q21 (15). It is
important to remember that the molecular events leading to the development of
pancreatic adenocarcinoma are not necessarily isolated events and that they often
represent underlying overall instability in the genome.
As mentioned previously, this genomic instability is an early event, seen in low
grade PanIN lesions. Evidence of this at that stage is made apparent by shortening of
telomeres seen in over 90% of PanIN lesions (4). It is thought that this early loss of
telomere length initiates a state of genomic instability by leaving chromosomes
vulnerable and sets the stage for future molecular events to occur.
In general, changes in K-ras, p53, INK4A, and SMAD4 provide a solid base for
the transformation of a normal pancreatic epithelial cell into an invasive pancreatic
adenocarcinoma. It is clear, however, that these changes do not solely contribute to
PDAC development and that there is a vast array of molecular events that can occur in
different combinations to produce an invasive cancer. The additional examples
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discussed above (only a representative sample of the vast number of possible
molecular changes) show how different the normal functions of these proteins can be
and illustrate how the changes that contribute to PDAC development are very much
widespread across the genome. Despite some of their differences of origin or function,
they often work synergistically to encourage cancer development.
The correct sequence of these changes plays an important role as well. An early
oncogenic mutation of K-ras helps to start the push of proliferative pressure on a cell.
The loss of gatekeeper tumor suppressors later in development relieves any final hold
on the growth of the progressing cancer. These timed events are important and, with
the addition of all of the other potential molecular changes, result in the development of
an invasive cancer that is aggressive, nearly impossible to treat, and ultimately and
unfortunately, fatal.
IV.

Apoptosis and the Bcl-2 family of proteins

Apoptosis is a biological process that is integral to normal physiological functions
and maintenance of homeostasis in an organism. The cell’s ability to undergo
apoptosis is a consequence of a vast array of complex cellular processes that involve
multiple proteins. Apoptosis can occur through two distinct, but interrelated, pathways:
the extrinsic pathway of apoptosis or the intrinsic/mitochondrial pathway of apoptosis
(Figure 1). The extrinsic pathway involves activation of cell surface death receptors
(Fas, TNFR) by extracellular ligands such as FasL or TNF. Activation of any of the
death receptors results in cleavage and activation of caspase-8, leading to a signaling
cascade that culminates in death of the cell. The intrinsic pathway, which can be
initiated by a variety of stress signals, involves permeabilization of the outer membrane
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of the mitochondria, which leads to cytochrome c release. Once released, cytochrome
c binds to Apaf-1 and forms the apoptosome, which results in cleavage and activation of
caspase-9 and, ultimately, cell death (19). This mitochondrial pathway is controlled
primarily by the complex interactions of the Bcl-2 family of proteins.
Bcl-2 is the founding member of this family of proteins and was discovered in studies
of B-cell lymphoma. The proteins in this family share certain sequence homology via
the presence of Bcl-2 homology (BH) domains. There are four BH domains that exist in
this family and each member has at least one. The family is divided into two groups:
one group that has pro-apoptotic effects and one group that has anti-apoptotic effects.
The pro-apoptotic group is further divided into two subgroups: one group containing
proteins such as Bax and Bak and a second group containing proteins including Noxa,
PUMA, Bim, and Bid. The latter group is often referred to as the BH3 only proteins, as
the members of this subgroup share sequence similarity to the rest of the family only
through their BH3 domain. The anti-apoptotic group includes the proteins Bcl-2, Mcl-1,
Bcl-XL, Bfl-1/A1 and Bcl-w (20).
Apoptosis through the intrinsic pathway is imminent when mitochondrial outer
membrane permeabilization (MOMP) occurs. This process arises as the result of the
formation of homo/heterodimers of the pro-apoptotic proteins Bax and Bak. The other
two groups of proteins in this family ultimately regulate apoptosis by either promoting or
inhibiting this dimerization. The Bcl-2 family of proteins does this through physical
interactions with each other. Two different models have been proposed to describe
precisely how this process might occur (Figure 2).
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The first scheme is an ‘indirect activation model’. In this model, the anti-apoptotic
proteins bind to Bax/Bak and block dimerization. The BH3 only proteins exert their proapoptotic actions by binding to the anti-apoptotic proteins, thereby displacing Bax and
Bak. Free Bax and Bak are now free to form dimers resulting in MOMP. The second
theory is a ‘direct activation model’ that is somewhat more complicated. In this model,
the BH3 only proteins are divided into sensitizer and activator proteins. In this model,
Bax/Bak oligomerization occurs when the activator BH3 only proteins bind to and
activate Bax/Bak. The goal of the anti-apoptotic proteins is to bind the activator proteins
and prevent them from binding and activating Bax/Bak. Accordingly, the sensitizer BH3
only proteins bind the anti-apoptotic proteins and prevent them from interacting with the
activator BH3 only proteins (21). Ultimately, it is likely that these two models may both
occur, since apoptosis regulation is all about balance. At a given point in the life of a
cell, the ratio of pro-apoptotic to anti-apoptotic proteins dictates whether the cell will
survive or undergo apoptosis. When the pro-apoptotic proteins are expressed in
greater quantity, the balance is pushed toward apoptosis. However, when the ratio
favors the anti-apoptotic proteins, cell survival will be the net consequence.
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Figure 2: Two proposed hypothetical models of the mechanism of action of
the Bcl-2 family of proteins. The “indirect activation model” describes a scenario in
which the binding of anti-apoptotic proteins inhibits Bax/Bak oligomerization.
Displacement of these anti-apoptotic proteins by a BH3 only protein allows dimers to
form and apoptosis to occur. In contrast, the “direct activation model” holds that BH3
only proteins are divided into two classes: activators and sensitizers. The activator
proteins bind to Bax or Bak, activating them and leading to apoptosis. The antiapoptotic proteins function in this model by binding to these activator and sensitizing
proteins and sequestering them. The BH3 only sensitizers bind to anti-apoptotic
proteins in an attempt to displace the activator BH3 proteins. When enough activator
BH3 proteins are free, they are able to activate Bax/Bak and induce apoptosis.
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V.

Mcl-1 (myeloid cell leukemia-1)

Mcl-1 was the second member of the Bcl-2 family discovered. Kozopas et al. (22)
were investigating the human myeloid leukemia cell line, ML-1. Their goal was to
differentiate ML-1 cells into monocytes/macrophages and identify genes whose
expression was increased during this differentiation process. One of the early induction
genes identified through this strategy was named Mcl-1 (myeloid cell leukemia-1) and
was shown to have sequence similarity to the previously identified protein, Bcl-2. Based
on this similarity and its mode of isolation, Mcl-1 was predicted to play significant roles
in cell differentiation and death (22). Future studies showed that c-myc-induced
apoptosis in CHO cells was delayed by Mcl-1 overexpression, illustrating that Mcl-1
indeed contributed to the regulation of the cell death process (23).
Since its discovery in 1992, studies of Mcl-1 have revealed this to be an intriguing
protein, which performs a fundamental role in cell physiology. Mcl-1 is an anti-apoptotic
member of the Bcl-2 family of proteins and contains three BH domains. This is unlike
the other anti-apoptotic members, which contain four BH domains. Despite this fact, it
is the largest of the proteins, containing 350 amino acid residues (24). Mcl-1 is also
different than other pro-survival proteins due to its N-terminus, which is larger than that
of other Bcl-2 family proteins and has been shown to affect Mcl-1’s function and
localization (25). It also contains two proline (P), gluatamic acid (E), serine (S), and
threonine (T) (PEST) sequences (22) which may account for its relatively short half life
(i.e., 2-3 hr), as these regions have been shown to target proteins for degradation (26).
The structural differences seen between Mcl-1 and the other prosurvival Bcl-2
proteins account for some of the differences seen in binding partners among these
18

proteins. The anti-apoptotic proteins all generally function in the same way as
described above, but the pro-apoptotic proteins with which they specifically interact
differ. For example, Mcl-1 binds with high affinity to the BH3-only protein Noxa, but
does not bind to Bad. In contrast, Bcl-2 binds well with Bad, but not as well with Noxa
(24).
Mcl-1 retains an alpha helical fold, similar to the other proteins, but differs in the
exposed surface of its binding groove. In addition to simply having different residues,
this groove is more electropositive than the other anti-apoptotic proteins. It is flanked on
either side by positive electrostatic potential and contains multiple histidine residues.
Proteins like Bcl-XL, however, have grooves that are almost completely uncharged.
Furthermore, there are differences in the positions of some surface helices of Mcl-1,
adding to the differences between this protein and its other family members (27). These
structural differences become very important in the development of inhibitors of these
proteins.
Mcl-1 is regulated at multiple levels, including transcriptional and translational.
Transcriptionally, Mcl-1 expression can be induced by a variety of cytokines and
signaling pathways, including the PI3K/AKT, Stat-3, and p38/MAPK pathways (28)
Additionally, alternative splicing of Mcl-1 results in two protein isoforms, Mcl-1L and Mcl1S. Interestingly, the Mcl-1S isoform behaves in a manner opposite to that of the normal
protein, functioning to promote apoptosis, much like the BH3 only proteins (29). At the
translational level, many studies have highlighted the role of microRNAs in Mcl-1
regulation. Mott et al. (30) identified mir29b as targeting Mcl-1 in studies comparing
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cholangiocarcinoma cells to normal cholangiocytes. Additional studies have implicated
this microRNA in Mcl-1 regulation in other cell types as well (31,32).
Mcl-1 also contains multiple phosphorylation sites in its PEST region. Multiple
proteins resulting in different outcomes mediate the phosphorylation of these sites.
Thr163 can be phosphorylated by ERK leading to the increased half-life of the protein
(33). Conversely, GSK-3 mediated phosphorylation of Ser159 leads to increased
ubiquitination and degradation of Mcl-1 (34). As previously noted, Mcl-1 has a very
short half-life. This is due to its rapid degradation in the cell, primarily through the
proteasome. Proteasome-mediated degradation of Mcl-1 can occur through a variety of
mechanisms, GSK-3-mediated phosphorylation representing the most highly
investigated of these. Mcl-1 Ubiquitin Ligase E3 (MULE) has been shown to
ubiquitinate Mcl-1 on 5 different lysine residues and to be the primary mediator of
normal Mcl-1 degradation (35). Additionally, Mcl-1 can be targeted for degradation
through interactions with additional proteins such as Noxa and the tumor suppressor
SCFFBW7 (28,36).
A. Role of Mcl-1 in Cancer
Mcl-1 is highly expressed in a variety of human cancer cell lines including breast, CNS,
colon, lung, ovarian, prostate, renal, and melanoma (Table 1)(37). Human melanoma
cell lines express Mcl-1, though they do not show increased expression when compared
to normal melanocyte controls. However, studies done in paraffin sections of benign
nevi, primary melanoma, and metastatic melanoma showed an increase in Mcl-1
expression that correlated with melanoma progression (38,39).
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Mcl-1 overexpression is exploited by cancer cells to evade cell death, i.e. to
survive, and as a mechanism for developing resistance to diverse chemotherapeutic
agents. The other anti-apoptotic members of the Bcl-2 family of proteins are also
frequently overexpressed in cancers, although they will not be discussed in this review.
Although overexpression of Mcl-1 does not result in increased cell proliferation, its
ability to suppress apoptosis is an important contributor to the transformed state. As
noted earlier, apoptosis regulation is based on the balance between pro- and antiapoptotic proteins within cells. The ability of a cancer cell to shift the balance toward
survival provides it with a major advantage in protecting itself from toxic factors. The
clinical implications of this phenomenon may be manifested by chemoresistance. For
example, while chemotherapeutic agents operate through a variety of mechanisms,
many of them are believed to act through initiation of apoptosis in a cell. Consequently,
protection from apoptosis via overexpression of Mcl-1 may represent a significant
barrier to the effectiveness of chemotherapeutic agents.
Dysregulation of Mcl-1 is an important genomic change in diverse cancers, many
of which become dependent upon this protein for survival as well as resistance to
chemotherapy. Indeed, numerous reports have documented the importance of this
protein in transformed cell survival. Thallinger et al. (40) reported that Mcl-1 antisense
oligonucleotides (ASO) resulted in decreased Mcl-1 expression in cell lines in vitro and
in tumors in vivo, and that Mcl-1 ASO treatment given by paraspinal infusion of SCID
mice with melanoma subcutaneous tumors resulted in tumor sensitization to the
chemotherapeutic drug, DTIC, accompanied by increased levels of apoptosis in tumor
cells (40). In a study of head and neck cancer, twenty-six tumor samples from patients
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with locally advanced head and neck cancer showed a 92% increase in Mcl-1
expression (41). Transfection of Mcl-1 ASO in a head and neck squamous cell
carcinoma cell line promoted cytotoxic synergy when combined with chemotherapeutic
agents, Paclitaxel and Cetuximab (42). Additionally, Mcl-1 is overexpressed in
hepatocellular carcinoma (HCC). Sieghart et al. (43) showed that human tumor
specimens overexpressed Mcl-1. They went on to show that the use of Mcl-1 ASO
induced apoptosis in HCC cells and sensitized them to cisplatin (43). Additionally, Mcl1 ASO decreased cell viability and induced apoptosis in multiple human myeloma cell
lines as well as two primary myeloma cell lines. This result was not seen following Bcl-2
or Bcl-XL ASO treatment (44). Pancreatic adenocarcinoma is another cancer that
overexpresses Mcl-1. Studies have shown that knockdown of Mcl-1 in a pancreatic
cancer cell line leads to decreased cell viability and colony formation in vitro and
decreased tumor size and weight in xenograft models. Furthermore, loss of Mcl-1
sensitized these resistant cells to the current first line treatment for pancreatic cancer,
Gemcitabine (45).
Mcl-1 has been shown to play important roles in lymphomas and leukemias as
well. In mantle cell lymphoma, Mcl-1 overexpression correlated with high-grade
morphology, high levels of proliferation, and p53 overexpression (46).

Additionally,

mice expressing a Mcl-1 transgene were shown to develop B cell lymphomas at a
frequency of 85% over a period of 2 years (47). In both acute and chronic leukemias,
Mcl-1 has been demonstrated to be extremely important for cancer survival, with siRNA
knockdown of Mcl-1 leading to apoptosis in cell lines. Furthermore, patients who show
resistance to Rituximab, an anti-CD20 antibody used to treat B-cell malignancies,

22

exhibit increased levels of Mcl-1. Mcl-1 knockdown has also been demonstrated to
sensitize cells to Rituximab treatment (48).
VI. Strategies employed in targeting Mcl-1
There have been numerous approaches designed to target Mcl-1. Some of
these schemes focus primarily on Mcl-1, but the majority of strategies target multiple
anti-apoptotic proteins in the Bcl-2 family. Here we review the most significant inhibitors
developed to date.
A. Drugs that result in Mcl-1 Downregulation
There are multiple drugs that, despite not being designed to specifically target Mcl-1,
display a mechanism of action that involves downregulation of Mcl-1. Studies with
these drugs provide continued evidence of the importance of this protein in
maintenance and progression of the cancer phenotype.
1. Cyclin-dependent kinase inhibitors
Flavopiridol

Flavopiridol is a semisynthetic flavonoid that functions as a cyclin-dependent kinase
inhibitor by competing for the kinase active site. It is able to inhibit the activity of
multiple CDKs and results in G1/S and G2/S cell cycle arrest (49). Flavopiridol also
globally decreases transcription levels in the cell via inhibition of P-TEFb and it can also
bind double stranded DNA (50). However, one of the more interesting observations
seen with Flavopiridol was its ability to downregulate Mcl-1 protein levels in B-cell
chronic lymphocytic leukemia cells (51). Notably, significant activity was observed in
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patients with high-risk CLL treated with a hybrid infusional flavopiridol schedule. This
new dosing regimen included a 30-minute loading dose prior to 4 hours of infusion given
weekly for 4-6 weeks. A group of 42 patients with refractory CLL were studied and of
those 42, 45% showed a partial response. Importantly, genetically high-risk patients
with del(17p13.1) showed a 42% response rate and those with del(11q22.3) a 72%
response rate (52).

Further studies in breast cancer showed that Flavopiridol treatment
synergistically enhanced the toxicity of the ERBB1/ERBB2 inhibitor Lapatinib in a Mcl-1dependent manner. The combination of Lapatinib and Flavopiridol increased the rate of
reduction of Mcl-1 protein compared to Flavopiridol alone. Moreover, overexpression of
Mcl-1 induced resistance to this combination (53). In studies involving human leukemia
cells, Flavopiridol interacted synergistically with the HDAC inhibitor Vorinostat through a
mechanism involving Mcl-1 down-regulation (54).

Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. It
has been studied in a variety of cancer types and has shown moderate effects in some
neoplastic diseases. Dose-related toxicities, which include neutropenia and diarrhea,
have limited some studies (50,55). Interestingly, one study looking at a combination of
Flavopiridol and Cisplatin/Carboplatin in solid tumors suggested that the lack of
significant activity seen may be the result of the failure to achieve decreases in Mcl-1
levels in tumors (50). Nevertheless, there is preclinical evidence of synergism between
Flavopiridol and proteasome inhibitors associated with Mcl-1 down-regulation (56,57).

SNS-032
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Another cyclin-dependent kinase inhibitor, SNS-032 was originally identified in a
screen developed to identify specific inhibitors of Cdk2. This compound has since been
shown to also inhibit Cdk7 and Cdk9 as well. SNS-032, like Flavopiridol, also shows
strong cytotoxic effects in vitro and results in decreases in anti-apoptotic proteins such
as Mcl-1 (58). Unfortunately, this compound exhibited disappointing results when
evaluated in clinical trials (59).

2. Sorafenib

Sorafenib is a multi-kinase inhibitor that was originally developed as an inhibitor
of B-Raf, but was subsequently shown to inhibit multiple other kinases, including
PDGFR, FLT, Kit, and VEGFR. In human leukemia cells, pharmacologically achievable
concentrations of sorafenib induced apoptosis through a mechanism involving Mcl-1
down-regulation (60-62). This has been found to be due to inhibition of translation
resulting from sorafenib-induced ER stress (60).

3. Deubiquitinase Inhibitors
WP1130
As discussed previously in this review, Mcl-1 is degraded rapidly in the cell via a
proteasome-dependent pathway. Blocking the proteasome can lead to increased levels
of Mcl-1 protein. Mcl-1 can also be rescued from degradation by deubiquitinases
(DUBs), which are able to remove ubiquitin from ubiquitinated Mcl-1. In a study
investigating interactions between Mcl-1 and other proteins in the cell, Schwickart et. al.
(63) found that one of the proteins that co-immunoprecipitates with Mcl-1 is the DUB
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USP9X. This group hypothesized that this interaction might lead to increased stability
of Mcl-1 and play an important role in cancers that overexpress Mcl-1. Indeed, they
showed that USP9X, in addition to Mcl-1, was overexpressed in samples of ductal
adenocarcinoma, colon adenocarcinoma, and small cell lung cancer. Additionally,
USP9X overexpression was found to correlate with poor prognosis in multiple myeloma.
Knockdown of USP9X via siRNA resulted in decreased Mcl-1 protein levels, but not
RNA levels, supporting the suggestion that USP9X knockdown results in increased Mcl1 degradation. This knockdown also led to increased sensitivity of colon carcinoma and
leukemia cells lines to ABT-737, a compound discussed later in this review, which are
usually resistant to this agent (63).
WP1130 is a small molecule that has multiple anti-cancer effects. It has been
shown to induce removal of Bcr-Abl from the cytoplasm into aggresomes, where it is not
able to facilitate oncogenic signaling. Additionally and most interesting for this review, it
directly inhibits USP9X. When used as a treatment in CML, WP1130 results in
decreased levels of Mcl-1, compartmentalization of Bcr-Abl, and the induction of
apoptosis (64).
B. Antisense oligonucleotide (ASO) treatment
Despite the fact that there are many studies looking at the effects of Mcl-1 ASO
treatment on cancer in vitro and in animal models in vivo, there is no report of a Mcl-1
ASO treatment being effectively translated into the clinic. This is likely due to the issues
that can arise with the use of ASO treatment in patients. In the human body, ASO have
an extremely short half-life, which makes achieving sufficient blood concentrations
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difficult. This is partly due to the ability of DNases to degrade them. Delivery of ASO is
also an issue, as it is difficult to direct ASO to their specific cellular target (65).
C. BH3 Mimetics
The concept of BH3 mimetics has been one of the most promising translational
strategies. As discussed, pro-apoptotic or anti-apoptotic effects arise, ultimately, as a
result of physical interactions between the anti-apoptotic Bcl-2 protein and the BH3
proteins. The anti-apoptotic proteins contain a hydrophobic binding pocket made from
the folding of their BH1, BH2, and BH3 domains. The BH3 domain of the BH3 only
proteins fits into and binds this hydrophobic pocket (66). Based on this modeling
prediction, small molecules have been developed that mimic the BH3 domain and
therefore are able to fit into the hydrophobic pocket of the anti-apoptotic proteins and
block their ability to bind pro-apoptotic proteins, inhibiting their function. Some of these
mimetics have been developed through structural studies and others through screening
studies. Regardless of how these drugs were discovered, they represent a novel and
exciting new strategy in cancer therapeutic development.
1. ABT-737

One of the most successful and well studied BH3 mimetics, ABT-737, was
discovered using NMR-based screening and demonstrated strong binding affinity to the
Bcl-2 family anti-apoptotic proteins Bcl-2, Bcl-XL, and Bcl-w. ABT-737 does not bind to
Mcl-1 or Bfl-1. This difference in affinity is due to differences in the structures of these
proteins as was described previously in this review. Initial studies showed that ABT-737
was effective in inducing cytotoxicity as a single agent in follicular lymphoma and small
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cell lung carcinoma (SCLC) cell lines. Additionally, it was found to enhance the lethality
of paclitaxel in NSCLC (non small cell lung carcinoma) (67). Subsequently, ABT-737
has been widely studied in a variety of cancers. It has been shown to induce
cytotoxicity both in vitro and in vivo in leukemia and lymphoma, glioblastoma, multiple
myeloma, and SCLC (68-72). Despite many promising studies in these cancer types,
there remain a large percentage of cancers that are resistant to ABT-737. This
resistance has been shown to stem from an overexpression of Mcl-1, one of the antiapoptotic proteins to which ABT-737 does not bind. Even within cancers that are
sensitive to ABT-737, specific cell lines that express higher levels of Mcl-1 display
increased resistance to this compound (68). Mcl-1-dependent ABT-737 resistance has
been consistently shown in the literature and multiple studies document that
downregulation of Mcl-1 through a variety of mechanisms is able to induce sensitivity to
ABT-737 (73-76). Notably, the CDK inhibitor roscovitine dramatically increased ABT737 lethality in human leukemia cells through a mechanism involving Mcl-1 downregulation (77).

Phase I/II clinical trials with ABT-263, an orally available form of ABT-737 with a
longer half-life, are in progress in patients with SCLC, leukemia, and lymphoma. Thus
far, studies in chronic lymphocytic leukemia (CLL) and SCLC have shown this drug to
be well tolerated, with some potentially manageable toxicities including back pain,
nausea/vomiting, diarrhea, and thrombocytopenia (78). More advanced clinical trials,
however, have shown limited efficacy of this drug as a single agent in SCLC (79).
2. Obatoclax (GX15)
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Obatoclax is another example of a BH3 mimetic. This mimetic differs from ABT737 in that in addition to targeting Bcl-2, Bcl-XL, and Bcl-w, it also binds to and inhibits
Mcl-1 and Bfl-1. Studies have shown that this compound induces cytotoxicity in a
number of cancer types including, but not limited to, NSCLC and a variety of leukemias.
Additionally, it has shown synergy when combined with various conventional
chemotherapeutic agents (53,80-83). Obatoclax also serves to again illustrate the
importance of Mcl-1 in cancer. Studies have shown that this compound’s cytotoxic
effects are partially mediated through specific effects on Mcl-1. Obatoclax can disrupt
the constitutive Bak-Mcl-1 interaction on the outer mitochondrial membrane (84). This
compound has advanced to clinical trials and Phase I studies in a variety of cancer
types have shown it to be fairly well tolerated, with neurologic toxicities being the most
common adverse event seen. Some evidence of efficacy was seen in these studies,
though ongoing Phase II trials will ultimately determine the effectiveness of this agent
(85-87).
3. Gossypol
Gossypol is a polyphenolic aldehyde derived from cottonseed. Original studies
with this extract focused on its ability to function as a male contraceptive (88).
However, it has also been shown to have potent anti-cancer activity. Gossypol functions
as a typical BH3 mimetic and binds to and inhibits the Bcl-2 anti-apoptotic proteins Bcl2, Bcl-XL, and Mcl-1 (89). Many groups have shown Gossypol to exhibit anticarcinogenic effects toward a wide variety of cancer types both in vitro and in vivo,
including, but not limited to, breast, prostate, glioma, and colon cancer (88,90-93).
LeBlanc et al. (94) also demonstrated Gossypol’s ability to inhibit growth of adrenal
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gland carcinoma cells, medullary thyroid carcinoma cells, ovarian carcinoma cells, and
endometrial carcinoma cells. Compared to ABT-737, Gossypol displays toxicity against
a much wider array of cancer types, possibly due to its ability to target Mcl-1. This
compound has been evaluated in Phase II clinical trials as a single-agent in patients
with advanced malignancies as well as in clinical trials that evaluated Gossypol in
combination therapy with conventional chemotherapeutics (95-98).
The presence of two reactive aldehyde groups on Gossypol, combined with initial
clinical trial results that showed difficulty in achieving sufficient Gossypol blood
concentrations, prompted groups to create Gossypol derivatives. Apogossypol was the
first derivative designed and showed better efficacy and less toxicity than its parent
compound (99). To date, there have been many such derivatives created with varying
binding affinities to the Bcl-2 anti-apoptotic proteins.
4. Sabutoclax (BI-97C1)
Sabutoclax (BI-97C1) is one of the newest Apogossypol derivatives developed
by Wei et al. (89,100). This novel compound binds to the Bcl-2 anti-apoptotic proteins
Bcl-2, Mcl-1, Bcl-XL, and Bfl-1. It was originally identified for its ability to bind Bcl-XL
with low to submicromolar binding affinity. Competitive fluorescence polarization
assays showed that BI-97C1 inhibited Bcl-XL with an IC50 value of .31 mM. Further
assays showed that this compound also had displacement activity against Bcl-2 (IC50 =
0.32 mM), Mcl-1 (IC50 = 0.20 mM), and Bfl-1 (IC50 = 0.62 mM) (100).
Sabutoclax induced apoptosis in the large B-cell lymphoma cell line, BP3, which
expresses high levels of Mcl-1 and Bfl-1 and is resistant to ABT-737. Furthermore,
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while toxic to wild type mouse embryonic fibroblasts, this compound showed only slight
toxicity against BAX/BAK double knockout MEF cells. This provided evidence that
Sabutoclax only has minimal off-target effects. Additionally, as Sabutoclax showed
efficacy against a cell line that overexpressed Mcl-1, unlike some earlier compounds
like ABT-737, it was evaluated in the context of a prostate cancer xenograft involving
M2182 cells, which rely on Mcl-1 for survival. A dose of 3 mg/kg induced nearly 60%
tumor inhibition, while a dose of 5 mg/kg nearly eliminated the tumors (100).
5. BH3-M6
This BH3 mimetic is a very new compound designed to inhibit Bcl-2, Bcl-XL, and
Mcl-1. It has been shown to disrupt the interactions between these proteins and the
pro-apoptotic BH3 only proteins. In the lung adenocarcinoma cell line, A549, this
compound induced apoptosis through cytochrome c release from the mitochondria.
Preliminary studies, however, showed high doses of this compound (doses of 25 and 50
mM) were needed to induce apoptosis. Additional studies with this compound in other
cancer types will be useful in determining the efficacy of this new BH3 mimetic (101).
VII. Functional Redundancy Among the Bcl-2 Family
As discussed previously, the majority of compounds that target Mcl-1 also affect
other members of the anti-apoptotic Bcl-2 family of proteins. This reflects structural and
functional redundancy in many protein members of this gene family. While some
cancers rely more heavily on Mcl-1 (44), others rely on alternate anti-apoptotic
members of the family for survival and progression (100). Accordingly, one might try to
identify and employ therapies for a particular cancer based on such reliance. Indeed,
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there have been compounds, such as ABT-737, that do not target all of the antiapoptotic Bcl-2 proteins. This compound is most effective in cancers that rely on
proteins targeted by ABT-737. However, the limitations observed with ABT-737
highlight why targeting of specific anti-apoptotic proteins alone may not promote optimal
therapeutic outcome.
In addition to a lack of efficacy against cancers reliant on Mcl-1 and Bfl-1,
multiple studies have now shown that, over time, cells sensitive to ABT-737 begin to
develop resistance to the drug by upregulating the anti-apoptotic proteins that it does
not target, i.e., Mcl-1 and Bfl-1. Yecies et al. (102) showed that lymphoma cells
subjected to long-term exposure of ABT-737 developed resistance via transcriptional
upregulation of Mcl-1 and Bfl-1. They further demonstrated that decreasing Mcl-1
protein levels via multiple mechanisms resulted in restored sensitivity to ABT-737 (102).
Previously, a similar phenomenon was also seen in acute myeloid leukemia (AML) cells.
This group noticed a positive correlation between Mcl-1 expression and ABT-737
resistance (101). These studies indicate that the Bcl-2 family of anti-apoptotic proteins
may provide overlapping compensatory functions when one of the proteins is lost. This
supports strategies involving compounds that target all of the anti-apoptotic proteins, as
this approach may help prevent the development of resistance mechanisms to BH3
mimetics.
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Chapter 2: Novel combinatorial therapy for pancreatic cancer:
a BH3 mimetic and a synthetic tetracycline

Introduction:
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer that is
predicted to cause almost 40,000 deaths in the US this year (NCI 2014). PDAC is fairly
resistant to most standard therapies and results in a 5-year survival rate of about 4%(1).
These dire statistics, combined with the fact that there have been minimal new
therapies developed for PDAC over the last decade, highlight the need for new
approaches to effectively treat this invariably fatal disease.
The aggressive nature and dismal prognosis of patients with pancreatic cancer
results partly from the plethora of molecular changes that occur during PDAC
development, one of which is overexpression of the anti-apoptotic proteins of the Bcl-2
family (103-106). Cancer cells exploit this overexpression to evade cell death and as a
mechanism promoting resistance to diverse chemotherapeutic agents.

Apoptosis

reflects a balance between pro- and anti-apoptotic proteins within cells. The ability of a
cancer cell to shift the balance toward survival promotes resistance to toxic factors
(107).
Consequently, the anti-apoptotic Bcl-2 proteins have emerged as a novel
therapeutic target. While multiple strategies have attempted to target these molecules,
BH3 mimetics have shown significant promise. Pro-apoptotic or anti-apoptotic effects in
cells arise, ultimately, as a consequence of physical interactions between anti- and pro-
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apoptotic Bcl-2 proteins (66,72). Based on modeling predictions of these interactions,
small molecules have been developed that mimic the BH3 domain of pro-apoptotic
proteins and bind to the anti-apoptotic proteins, thereby impeding their ability to inhibit
apoptosis.

These drugs represent a novel and exciting new strategy in cancer

therapeutic development (107).
Sabutoclax (BI-97C1) is a novel Apogossypol derivative BH3 mimetic developed
by Wei et al. (89,99,100,108). This compound binds to the Bcl-2 anti-apoptotic proteins
Bcl-2, Mcl-1, Bcl-XL, and Bfl-1. It was originally identified based on its ability to bind BclXL with low to submicromolar binding affinity (100). We have previously shown that
Sabutoclax shows efficacy against prostate and colorectal cancers, two cancers that
also overexpress anti-apoptotic Bcl-2 proteins (109,110).
Minocycline is a synthetic tetracycline antibiotic that displays marginal activity
against multiple cancers (111-115).

However, less than stellar outcomes have

diminished enthusiasm for using these drugs in cancer research. The marginal single
agent effects of Minocycline against cancer may be due to the fact that it also impedes
cell death in the face of toxicity or injury by inhibiting mitochondrial apoptosis and
upregulation of Bcl-2 (116-118). In an attempt to develop a unique therapeutic strategy
for PDAC, we hypothesized that Sabutoclax and Minocycline might show therapeutic
efficacy against this disease when used in combination because of both the reliance of
PDAC on the Bcl-2 proteins for survival as well as the theoretical ability of Sabutoclax to
counteract the anti-apoptotic effects of Minocycline, thereby uncovering the true
therapeutic potential of this previously overlooked drug.
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Materials and Methods
Human Cell Lines

MIA PaCa-2, PANC-1, BxPC-3, AsPC-1, and HPNE cells were all obtained from the
American Type Culture Collection (ATCC). LT2 cells were purchased from Millipore.
MIA PaCa-2 and PANC-1 were maintained in DMEM plus 10% FBS. BxPC-3 and
AsPC-1 cells were maintained in RPMI plus 10% FBS. HPNE and LT2 cells were
maintained with media according to distributor’s instructions. Cell lines were expanded
and cryopreserved at early passages and new vials were thawed out and used for
experiments approximately every 3 months.
Creation of KPC Mouse Cell Lines
Cell lines were derived from the ascites of tumor bearing KPC mice. At the time of
necropsy, ascitic fluid was collected from the mice and centrifuged to pellet tumor cells.
The pellet was repeatedly washed in PBS and centrifuged before being resuspended in
RPMI supplemented with 4% FBS and placed in culture. This media was used to
maintain these cell lines.
Drugs and Drug Administration
For all in vitro studies, Sabutoclax (produced by Dr. Maurizio Pellecchia) was diluted in
DMSO and Minocycline (Sigma) in PBS. For combination treatments, Sabutoclax and
Minocycline were administered to cells simultaneously. zVAD-FMK (20 µM, Promega)
was incubated with cells for 1 hour prior to treatment with Sabutoclax and Minocycline.
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Caspase 8 specific inhibitor, z-IETD-FMK (20 µM, BD Pharmingen) was also incubated
with cells for 1 hour before treatment with Sabutoclax and Minocycline.
Proliferation Studies
5 x 103 cells were plated in 96-well plates and treated with Sabutoclax and/or
Minocycline for 72 hours. Proliferation was assessed by MTT assay as previously
described (119). All data were normalized to the control.
Cell Death Assays
For Trypan Blue exclusion assays, 5 x 105 cells were plated in 6-cm dishes, treated as
indicated for 48 hours, and then assayed as previously described (120).
LDH Cytotoxicity Assays
5 x 105 cells were plated in 6-cm dishes and treated as described. After 48 hours,
media was collected from each dish and assayed according to the manufacturer’s
instructions (Cytotoxicity Detection Kit (LDH), Roche).
Cell Cycle Studies
1 x 106 cells were plated in 10-cm dishes and cultured in normal media with 0.5% serum
for 48 hours. Cells for the zero hour time point were collected and fixed at this point.
Remaining plates were kept in either normal media or 750 nM Sabutoclax for indicated
time points. Once all cells were collected and fixed, they were incubated with propidium
iodide and FACS was used for cell cycle analysis. Cell cycle studies were done as
previously described (121).
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Colony Forming Assay
MIA PaCa-2 cells were treated with Sabutoclax (500 nM), Minocycline (50 µM), or a
combination of both for 24 hours. Cells were then trypsinized and 1,000 cells were
plated into 6-cm plates in triplicate. Cells were allowed to grow and form colonies in
normal media for approximately 14 days.

Plates were then fixed and stained with

Giemsa.
Western Blotting
5 x 105 cells were plated in 6-cm dishes and treated as described. After 48 hours, whole
cell lysates were prepared and western blotting analysis was carried out as previously
described (120). Primary antibodies used for these studies are PARP (1:1,000), Stat3
(1:1,000), pStat3 (1:750), Mcl-1 (1:1,000), Survivin (1:750), p21 (1:750), p27 (1:1,000),
Cyclin D1(1:500), Caspase 2 (1:1,000), Caspase 3 (1:1,000), Caspase 6 (1:1,000),
Caspase 7 (1:1,000), Caspase 8 (1:1,000), Caspase 10 (1:1,000), Caspase 12
(1:1,000), AIF (1:1,000), pRB (1:750) (Cell Signaling), EF1- (1:1,000, Millipore), and
Actin (1:5,000, Sigma).

Densitometric analysis was done using ImageJ software

(National Institutes of Health).
Constructs and Transfection
Stat3Y705F Clones: MIA PaCa-2 or PANC-1 cells were transfected with a plasmid
expressing a mutated form of Stat3 (pRc.CMV.Stat3Y705F, Addgene). Clones were
selected with Neomycin for approximately 2 weeks and then picked and grown up
individually. Whole cell lysates were made and samples were used for western blotting
to characterize clones.

Luciferase Clones: MIA PaCa-2 or PANC-1 cells were
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transfected with pGL3.CMV.luc (Promega).

Transfections used Lipofectamine 2000

(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.
Immunohistochemistry
Tumors were fixed in formalin, embedded in paraffin, and sectioned for staining.
Staining was done as previously described (122) with anti-p-Stat3 (1:100, Abcam), antiPCNA (1:100, Abcam), and anti-Mcl-1 (1:100, Abcam) per the manufacturer’s
instructions.
Combination Index Calculation
Combination index (CI) values were determined for the combination of Sabutoclax and
Minocycline in MIA PaCa-2 cells. Values were calculated using CompuSyn software
(ComboSyn, Inc.) according to the Chou-Talalay method.
In vivo studies
Subcutaneous Xenograft Studies
5 x 106 MIA PaCa-2 and 3.5 x 106 PANC-1 cells were used to establish bilateral
subcutaneous tumors on the flanks of 8-10 week old male athymic nude mice. Studies
were done as previously described (109).
~100-mm3.

Treatment began when tumors reached

Sabutoclax was given at a dose of 1 mg/kg for both studies and was

dissolved in a 10:10:80 solution of 100% ethanol:Cremophor:PBS. Minocycline was
given at a dose of 20 mg/kg and dissolved in PBS. Both drugs were given via IP
injection 3 times per week. n = 5 mice/group
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Quasi-Orthotopic Xenograft Studies
Low Tumor Burden
In this model, we injected 1 x 106 MIA PaCa-2-luc cells IP into 8-10 week old male
athymic nude mice. We allowed 1 week for tumor cells to attach and grow and then
began treatment with PBS, 1 mg/kg Sabutoclax, 20 mg/kg Minocycline, or both
Sabutoclax and Minocycline. Sabutoclax and Minocycline were given via IP injection
3x/week. Mice were imaged by BLI at 3 weeks after treatment was initiated and then
sacrificed at 4 weeks. At time of sacrifice, mice were imaged pre-necropsy. After
necropsy, organs from a few mice/group were imaged to determine tumor specificity. n
= 7 mice/group
High Tumor Burden
5 x 106 MIA PaCa-2-luc cells were injected IP into 8-10 week old male athymic nude
mice. We allowed 1 week for tumor cells to attach and grow and then began treatment
with PBS, 1 mg/kg Sabutoclax, 20 mg/kg Minocycline, or both Sabutoclax and
Minocycline. Sabutoclax and Minocycline were given via IP injection 3x/week. Mice
were sacrificed at 4 weeks. The pancreas from each mouse was removed and weighed
during necropsy. n = 10 mice/group
BLI of Mice
During imaging, mice were placed in the imaging chamber and maintained with 2%
isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse.
Anesthetized mice were injected IP with 150mg/kg body weight D-Luciferin (Xenogen
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a
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charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS)
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA). The positive signal from
background-subtracted images was analyzed by Living Image software for integrated
density.
Syngeneic Mouse Study
KPC (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mouse cell line 48 was injected subcutaneously
into both flanks of non-tumorigenic KPC mice (Pdx-1-Cre negative/K-rasLSLG12D/p53flox/wt).

Tumors were inoculated 1 week prior to initiation of treatment. Mice

were treated with PBS, 1.5 mg/kg Sabutoclax, 10 mg/kg Minocycline, or both
Sabutoclax and Minocycline. Sabutoclax was dissolved in a 10:10:80 solution of 100%
ethanol:Cremophor:PBS. Minocycline was dissolved in PBS. Mice were treated with
Sabutoclax, Minocycline, or both drugs every 2-3 days via IP injection for a total of 6
injections.

Tumors were measured with calipers to obtain tumor volumes. n = 5

mice/group
Survival Study
KPC mice (Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox) were started on a Sabutoclax and
Minocycline treatment regimen at 1 month of age.

Mice were treated with a

combination of Sabutoclax (1.5 mg/kg) and Minocycline (10 mg/kg) via IP injection 3
times per week. Mice were kept on this treatment until reaching a moribund status. At
this point, mice were sacrificed and necropsied. Tumor sections were obtained from
these mice and subjected to immunohistochemistry. n = 12 mice (control group); n = 10
mice (Sabutoclax + Minocycline group).
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Statistical Analysis
The data presented are the mean + S.D. of the values from three independent
experiments. For in vivo studies, data shown are the mean + 95% confidence interval.
Significance was determined using the Student’s t-test.

p<0.05 was considered

statistically significant.

Results:
Sabutoclax inhibits cell growth and induces apoptosis in PDAC
Multiple PDAC cell lines, one immortalized pancreatic fibroblast cell line (LT2), and one
immortalized pancreatic epithelial cell line (HPNE) were treated with increasing doses of
Sabutoclax and assessed for effects on proliferation. The normal cell lines displayed
little change in cell growth (Fig. 3A-B), while all of the cancer cell lines were growth
inhibited. Interestingly, the sensitivity of the cancer cell lines varied, with some being
very sensitive to Sabutoclax (MIA PaCa-2) and others more resistant (AsPC-1) (Fig.
3A). The ability of Sabutoclax to induce cell death and apoptosis was also evaluated
through Trypan Blue assays and detection of the cleavage of PARP, a protein cleaved
by caspases during apoptosis (Fig. 4A-B). Again, MIA PaCa-2 was most sensitive to
Sabutoclax. However, despite not showing a potent cell death phenotype, cells like
AsPC-1 still showed profound growth inhibition following Sabutoclax treatment at higher
doses. Furthermore, Sabutoclax displayed greater growth inhibitory effects than the
BH3 mimetic ABT-737 (Fig. 5A-B).
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A

B

Figure 3: Sabutoclax inhibits cell growth and induces apoptosis in pancreatic
cancer cells. (A) Sabutoclax dose response curves via MTT proliferation assays in
pancreatic fibroblast cell line, LT2, and pancreatic cancer cell lines PANC-1, AsPC-1,
MIA PaCa-2, and BxPC-3. Experiments done in triplicate and independently repeated
three times. (B) Sabutoclax dose response curve via MTT proliferation assay in
pancreatic epithelial-derived cell line, HPNE. Experiments done in triplicate and
independently repeated three times.
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Figure 4: Sabutoclax inhibits cell growth and induces apoptosis in pancreatic
cancer cells. (A) Western blotting for PARP and EF1- (loading control). Data
representative of three independent experiments. (B) Trypan Blue assays in AsPC-1,
PANC-1, and MIA PaCa-2. **p<0.001 as compared to UT sample. Experiments done
in triplicate and independently repeated three times.
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Figure 5: Sabutoclax has greater efficacy than ABT-737. (A) MTT proliferation
assays 72 hours post treatment. (B) MTT proliferation assay comparing ABT-737 to
Sabutoclax. *p < 0.001. Experiments done in triplicate and independently repeated three
times.
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Sabutoclax induces G1-S phase arrest
Sabutoclax induces cell death in MIA PaCa-2 cells, without promoting potent cell
death in either AsPC-1 or PANC-1. Despite this, there is still a dramatic reduction in cell
growth after drug treatment in these cell lines. To interrogate the mechanism of growth
suppression in these cell lines, we performed cell cycle analysis via FACS analysis (Fig.
6-7). Sabutoclax increased the percentage of MIA PaCa-2 subG1 phase cells, which
have a DNA content less than 2n and are indicative of dead cells, after 24 and 48 hours,
without affecting cell cycle, which is consistent with our previous data (Fig. 6A,D). In
PANC-1 and AsPC-1 cells, however, potent G1-S phase cell cycle arrest was evident
(Fig. 6B-C). These experiments only evaluated cells up to 48 hours post-treatment. A
second set of experiments also included 72 and 96 hour time points (Fig. 8-9) to
determine if longer drug incubations promoted cell cycle arrest or resulted in a switch to
apoptosis. In AsPC-1, the G1-S phase arrest was sustained throughout all time points
evaluated (Fig. 8B). However, at 72 and 96 hours, PANC-1 showed an increase in the
subG1 population of cells, indicating that there is an initial cell cycle arrest in these cells
that later switches to apoptosis (Fig. 8A,C). These results emphasize the complexity of
responses observed in PDAC to a single agent, such as Sabutoclax.
Evaluation of cell cycle protein markers (Fig. 8D) confirmed decreased Cyclin D1
and increased p27 expression in AsPC-1 and PANC-1 cells. Additionally, there was a
dramatic decrease in levels of phosphorylated Rb (Ser780). This corresponded with the
observed G1-S phase arrest.

Interestingly, while levels of p21 in AsPC-1 cells

increased, p21 levels decreased in PANC-1 cells. This difference may account for the
switch from growth arrest to apoptosis in these cells (123,124).
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Sabutoclax

Figure 6: Sabutoclax causes a G1-S phase cell cycle arrest. (A-C) Cell cycle
analysis. (D) Percentage of cells analyzed in the subG1 phase, indicating cell death.
Data representative of three independent experiments.

A

B
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C

Figure 7: Sabutoclax causes a G1-S phase cell cycle arrest. (A-C) FACS analysis
data of graphs presented in Figure 6. Data representative of three independent
experiments.
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Figure 8. Sabutoclax causes a G1-S phase cell cycle arrest. (A-B) Cell cycle
analysis. (C) Percentage of cells analyzed in the subG1 phase, indicating cell death. (D)
Western blotting of whole cell lysates for Cyclin D1, Cyclin E, p27, p21, and phosphoRb. EF1- was used as a loading control. Data representative of three independent
experiments.
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A

Figure 9: Sabutoclax causes a G1-S phase cell cycle arrest. (A-B) FACS analysis
data of graphs presented in Figure 8. Data representative of three independent
experiments.
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Sabutoclax synergizes with synthetic tetracycline, Minocycline, in PDAC
It is now almost axiomatic that to successfully combat cancer multiple targeting
strategies used in combination will be necessary. Cancer cells develop resistance to
initially effective treatments and acquire avoidance mechanisms preventing toxicity.
Accordingly, combinatorial approaches attacking multiple pathways in a cancer cell can
increase drug efficacy, reduce toxicity, and increase the time to resistance. Based on
this concept, we sought to identify an agent that would promote synergy when
combined with Sabutoclax. Minocycline, a commonly used antibiotic, can negatively
impact cancer growth and survival (111-115). Despite this, it paradoxically also protects
cells in the face of an insult through inhibition of mitochondrial apoptosis and
upregulation of Bcl-2 (116-118). For these reasons, we hypothesized that these drugs
might work well in combination, given their cancer-selective toxicities as single agents
and the potential of Sabutoclax to counteract the pro-survival effects of Minocycline.
Minocycline is fairly nontoxic to several PDAC cells (MIA PaCa-2 and PANC-1),
but is inhibitory in others (AsPC-1 and BxPC-3) (Fig. 10).

In resistant cells, the

combination of Sabutoclax and Minocycline is very toxic and significantly reduces cell
proliferation and overall cell number, and induces cell death to a much greater extent
than either agent alone in MIA PaCa-2 (Fig. 11) and PANC-1 cells (Fig. 15-16).
Combination index values also demonstrate synergy between these two compounds
(Fig. 13). It also promotes increased apoptosis and reduced colony formation in PDAC
cells. Importantly, this synergistic effect is not evident in the non-cancerous cell line,
HPNE (Fig. 12).
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Figure 10: Pancreatic cancer cells exhibit varying levels of sensitivity to
Minocycline. MTT proliferation assay in MIA PaCa-2 and PANC-1 cells (A) and AsPC1 and BxPC-3 cells (B) 72 hours post treatment. Experiments done in triplicate and
independently repeated three times.
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Figure 11: The combination of Sabutoclax and Minocycline produce synergistic
cytotoxic effects. (A) MTT proliferation assay in MIA PaCa-2 cells 72 hours post
treatment. Experiments done in triplicate and independently repeated three times. (B)
Trypan blue assays evaluating cell death and cell numbers in MIA PaCa-2 cells 48
hours post treatment. **p<0.0001. Experiments done in triplicate and independently
repeated three times. (C) Western blotting of whole cell lysates for PARP expression in
MIA PaCa-2 cells 48 hours post treatment. Actin was used as a loading control. Data
representative of three independent experiments. (D) Colony forming assay in MIA
PaCa-2 cells. Experiments done in triplicate and independently repeated three times.
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Figure 12: The combination of Sabutoclax and Minocycline produce synergistic
cytotoxic effects. (A) MTT proliferation assays in HPNE cells 72 hours post treatment.
Experiments done in triplicate and independently repeated three times. (B) LDH
cytotoxicity assay in pancreatic epithelial cell line, HPNE. Experiments done in triplicate
and independently repeated three times. (C) Western blotting for PARP using whole cell
lysates from HPNE cells 48 hours post treatment. Data representative of three
independent experiments.
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Figure 13: Sabutoclax and Minocycline show synergy. Combination index (CI)
values for the combination of Sabutoclax and Minocycline in MIA PaCa-2 cells.

We next sought to define the mechanism underlying this synergy.

The

combination of subtoxic doses of Sabutoclax and Minocycline induced potent cell death
that was partially abrogated by pretreatment with zVAD, indicating that this toxic effect
is, in part, caspase-mediated. This rescue phenotype is evident in the morphology of
treated cells (Fig. 14A, 16) and through reductions in LDH activity, indicating lower
levels of cell death (Fig.14B, 15B). Furthermore, PARP cleavage was reduced in cells
pretreated with zVAD (Fig. 14C, 15A). When specific caspases were evaluated, the
combination treatment showed caspase-3 cleavage and loss of full-length caspase-8.
In zVAD-treated samples, caspase-3 cleavage was not seen at all and levels of fulllength caspase-8 were partially restored.
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Figure 14: The cytotoxicity induced by Sabutoclax and Minocycline is caspasedependent and dependent upon loss of Stat3 activation. (A) Phase contrast images
showing MIA PaCa-2 cells 48 hours post Sabutoclax and/or Minocycline treatment.
Experiments done in triplicate and independently repeated three times. (B) Media from
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plates photographed in panel A was collected and used for LDH activity assays.
*p<0.005 as compared to single drug treated samples. **p=0.006 as compared to 50 µM
Minocycline + Sabutoclax-treated samples. Experiments done in triplicate and
independently repeated three times. (C) Western blotting of whole cell lysates for
expression of PARP, caspase-3, and caspase-8. Actin was used as a loading control.
Data representative of three independent experiments.

A

B

Figure 15: Sabutoclax and Minocycline induce cytotoxicity in PANC-1 cells that is
reversed with zVAD. (A) Western blotting of whole cell lysates for expression of PARP
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48 hours post treatment. Actin was used as a loading control. Cells treated with zVAD
were incubated with the inhibitor for 1 hour prior to combination treatment. Data
representative of three independent experiments. (B) Media from plates used for
western blots in panel A was used for LDH activity assays. **p=0.01.

A
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Figure 16: Sabutoclax and Minocycline induce cytotoxicity in PANC-1 cells that is
reversed with zVAD. (A) Phase contrast images showing PANC-1 cells 48 hours after
treatment. Data representative of three independent experiments.

The cytotoxic effect of Sabutoclax and Minocycline is Stat3-dependent
Stat3 activation is clinically relevant for PDAC as constitutive activation of Stat3
has been reported in 30-100% of human tumor specimens, and is crucial for PDAC
initiation, progression, and maintenance (125). Sabutoclax treatment resulted in a
potent loss of Stat3 phosphorylation (Tyr 705), as well as a loss of downstream Stat3
targets, such as survivin (Fig. 17A). Minocycline alone induced similar changes (Fig.
17B). Subtoxic doses of each drug lowered Stat3 activation, but the combination of
both drugs almost completely eliminated pStat3 expression (Fig. 17C). To determine
whether this would affect the cytotoxicity of the combination, we created MIA PaCa-2
clones stably expressing an activated Stat3 mutant, Stat3 Y705F, e.g. C 13 (Fig. 18A).
As compared to the parental cell line, C 13 showed enhanced resistance to combination
treatment (Fig. 18B). A similar elevated resistance was observed in other Stat3 Y705F
overexpressing MIA PaCa-2 clones (data not shown). Because pretreatment with zVAD
partially rescued cells from Sabutoclax and Minocycline-induced cell death, we
evaluated expression of a variety of caspases to determine their potential involvement
not only in death induced by the combination, but which ones might be affected in C 13
cells (Figure 18C). In parental MIA PaCa-2 cells, caspases 3, 7, and 8 were cleaved.
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Loss of full-length caspases 2 and 6 was evident, whereas AIF, caspase 12, and
caspase 10 (caspase 10 data not shown) were not significantly altered. In C 13 cells,
however, we did not see any significant changes in any caspase examined, supporting
the observation that loss of Stat3 activation is necessary for caspase-dependent cell
death by Sabutoclax and Minocycline. We also created stable cell lines overexpressing
Stat3 Y705F in PANC-1 cells.

Similar to what we observed in MIA PaCa-2 cells,

constitutive Stat3 activation in these clones protected them from cytotoxicity induced by
the combination of Sabutoclax and Minocycline (Fig. 19).
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Figure 17: The cytotoxicity induced by Sabutoclax and Minocycline is caspasedependent and results in loss of Stat3 activation. (A-B) Western blotting of whole
cell lysates for pStat3 Tyr705, Stat3, Survivin, Actin (loading control) and EF1- (loading
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control) 48 hours post treatment. Data representative of three independent experiments.
(C) Western blotting of whole cell lysates for pStat3 Tyr705 48 hours post treatment.
Actin was used as a loading control. Cells were incubated with zVAD for 1 hour prior to
Sabutoclax and Minocycline treatment. Data representative of three independent
experiments.
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Figure 18: The cytotoxicity induced by Sabutoclax and Minocycline is dependent
upon loss of Stat3 activation. (A) Western blotting of whole cell lysates from MIAPaCa-2-Stat3Y705F stable clones for pStat3 Tyr705. Actin was used as a loading
control.
Graph below blot shows quantification. Data representative of three
independent experiments. (B) Western blotting of whole cell lysates for PARP in
parental MIA Paca-2 and Stat3Y705F stable clone 13. Actin was used as a loading
control. Sab = 500 nM Sabutoclax, Mino = 50 µM Minocycline. Data representative of
three independent experiments. (C) Western blotting of whole cell lysates 48 post
treatment for PARP, AIF, Caspase-7, Caspase-8, Caspase-12, Caspase-2, Caspase-6,
and Caspase-3. Actin was used as a loading control. Data representative of three
independent experiments.
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Figure 19: The cytotoxicity induced by Sabutoclax and Minocycline is dependent
upon loss of Stat3 activation. (A) Western blotting of whole cell lysates from PANC-1Stat3Y705F stable clones for pStat3 Tyr705. Actin was used as a loading control. (B)
Western blotting of whole cell lysates for PARP in parental PANC-1 cells and
Stat3Y705F stables clones 8 and 11. Actin was used as a loading control. Data
representative of three independent experiments.

Sabutoclax and Minocycline induce cytotoxicity through the intrinsic pathway of
apoptosis

65

Caspase-8 activation is an integral part of the extrinsic pathway of apoptosis.
However, it can also be activated independent of this pathway by other caspases (126).
To determine if caspase-8 involvement was due to extrinsic pathway activation or
downstream intrinsic pathway activation, we used Z-IETD-FMK to specifically inhibit
caspase 8 before drug treatment. Unlike the pan caspase inhibitor, zVAD, pretreatment
with Z-IETD-FMK did not protect cells from Sabutoclax and Minocycline-induced cell
death (Fig. 20). This indicates that caspase-8 activation is dispensable for Sabutoclax
and Minocycline-induced cell death and is most likely a secondary effect of other
caspases. Therefore, our data support the hypothesis that Sabutoclax and Minocycline
induce a cytotoxic phenotype through activation of the intrinsic pathway of apoptosis.
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Figure 20: The cytotoxicity induced by Sabutoclax and Minocycline works
through the intrinsic pathways of apoptosis. Western blotting 48 hours post
treatment for PARP and Actin (loading control). Cells were incubated with zVAD or zIETD-FMK for 1 hour prior to treatment with Sabutoclax and Minocycline. Data
representative of three independent experiments.
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Sabutoclax alone reduces tumor growth in a xenograft model of pancreatic
cancer and this effect is enhanced with the addition of Minocycline
Luciferase-expressing MIA PaCa-2 cells, displaying a similar phenotype as
parental cells (Fig. 21A), were established as subcutaneous xenografts in athymic nude
mice, which were then treated with Sabutoclax (1 mg/kg), Minocycline (20 mg/kg), or
both agents. Both drugs were given via IP injection 3x/week. Minocycline treatment
alone showed minimal effects, while Sabutoclax alone showed greater reductions in
tumor weight and growth (Fig. 21B-C). Despite this, animals treated with a combination
of Sabutoclax and Minocycline showed a synergistic reduction in tumor growth, with a
significantly smaller tumor growth rate, even as compared to Sabutoclax alone (Fig.
21C). This was confirmed with bioluminescence imaging (BLI) (Fig. 21D). A similar
experiment was conducted using PANC-1-luc cells resulting in the same trend, with the
combination group showing significant inhibition of tumor growth (Fig. 23).
Immunohistochemistry of tumor sections (Fig. 22) demonstrated higher intensity
proliferation marker PCNA staining in control, Sabutoclax, and Minocycline-treated
groups as compared to the combination-treated group.

Furthermore, combination-

treated tumors showed significantly less phosphorylated Stat3 expression, consistent
with in vitro observations.
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Figure 21: Sabutoclax reduces tumor growth in a subcutaneous xenograft model
and is enhanced by the addition of Minocycline. (A) MTT proliferation assay of MIA
PaCa-2 cells stably expressing luciferase after treatment with Sabutoclax and/or
Minocycline. ***p<0.0001. Experiments done in triplicate and independently repeated
three times. (B) Tumor weight as normalized to the control animals at the end of the
experiment. (C) Tumor growth kinetics of MIA PaCa-2-luc cell subcutaneous tumors on
the flanks of athymic mice. *p<0.04 as compared to all other groups. (D)
Bioluminesence imaging (BLI) of tumors and image quantification. Exposure time = 5
seconds. n= 5 mice/group.
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Figure 22: Sabutoclax and Minocycline reduce PCNA expression and Stat3
activation in vivo. Tumors were fixed in formalin, embedded in paraffin, and sectioned
for staining. Representative images of immunohistochemistry (IHC) stained with p-Stat3
Y705 and PCNA. Arrows in PCNA images show margin of negatively stained tumor
area at the periphery of each tumor. Data representative of three independent
experiments.
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Figure 23: Sabutoclax and Minocycline reduce tumor growth in a subcutaneous
xenograft model of pancreatic cancer. (A) Tumor growth kinetics of PANC-1-luc cell
subcutaneous tumors on the flanks of athymic mice. *p<0.04 as compared to all other
groups. (B) Bioluminesence imaging (BLI) of tumors. Exposure time = 8 seconds. n= 5
mice/group
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Quasi-orthotopic xenograft mouse model
While subcutaneous xenograft studies are useful in evaluating in vitro
observations in an in vivo setting, flank tumors do not accurately mimic natural disease
states. To study the effect of our drugs in a more natural setting, we used a quasiorthotopic model of PDAC (127). We found that MIA PaCa-2-luc cells, when injected
intraperitoneally, specifically homed to the pancreas, with the majority of tumors or
tumor nodules found in this organ. Other locations in which we found tumors (liver,
peritoneal lining) are common places for this cancer to metastasize and more closely
mimic the clinical picture of this disease.
In an initial set of experiments, we injected 1 x 10 6 cells i.p. and allowed 1 week
for tumor establishment before treating mice with Sabutoclax and Minocycline, alone or
in combination. Consistent with our previous data, Minocycline as a single agent did not
have any effect and mice presented similarly to control animals. Sabutoclax showed a
potent single-agent effect, with fewer animals showing evidence of disease.

The

combination group showed even more promise (Fig. 24C), with only 1/7 mice showing
tumors by BLI (Fig. 24A-B).

Pancreas weight did not show significant differences,

though the trend supported our other observations (data not shown).
A second quasi-orthotopic study was conducted using similar drug dosing
parameters.

Tumors, though, were initiated with the injection of 5 x 10 6 cells as

opposed to 1 x 106. In our first study, the use of fewer cells allowed testing whether
Sabutoclax and Minocycline could prevent tumor formation. However, the use of fewer
cells also means that the overall tumor burden was less when therapy was initiated,
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which prevented determining the true magnitude of the effect Sabutoclax and
Minocycline would have in the context of a greater tumor burden, which might more
closely imitate the clinical setting.
As anticipated, injecting a greater number of cells resulted in a larger overall
tumor burden in the animals. Mice from all groups developed tumors or tumor nodules
in the pancreas. However, the weight of the pancreas from mice treated with both
Sabutoclax and Minocycline was significantly less than those from animals in all 3 other
groups and visually showed fewer gross nodules (Fig. 24D).
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Figure 24: Sabutoclax and Minocycline reduce tumor growth in a quasi-orthotopic
xenograft model. (A) Low Tumor Burden study: BLI images of mice post treatment.
Exposure time = 5 seconds. (B) Image quantification of panel A. (C) Tumor incidence in
pancreas – measured by imaging and by gross examination of animals at necropsy. n=
7 mice/group. (D) High Tumor Burden study: pancreas weight at necropsy. Treatment
groups normalized to the control. *p=0.03, **p=0.01, ***p=0.004. n= 10 mice/group
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Sabutoclax and Minocycline in a transgenic mouse model of PDAC (KPC)
The KPC transgenic PDAC mouse model is used frequently in PDAC research
(128-132). This animal spontaneously develops precursor pancreatic lesions, PanINs,
which progress and eventually develop into invasive disease. Tumors form as a result of
activated K-ras and functional loss of p53 in the pancreas, genetic changes also seen in
a high percentage of human tumors.

Histological analysis shows extensive local

invasion as well as metastasis in a subset of animals (133).
Pancreatic tumors from these mice overexpress Mcl-1 as shown by
immunohistochemistry (Fig. 25A).

This is consistent with the disease observed in

humans (103-106) and provides a rationale for using Sabutoclax in these animals.
Additionally, cell lines derived from these animals show combination effects with
Sabutoclax and Minocycline (Fig. 25B). These cells were injected subcutaneously into
the flanks of control KPC mice (Pdx-1-Cre-negative/K-rasLSL-G12D/p53flox/wt) and allowed
to grow for approximately one week. Mice were treated with Sabutoclax, Minocycline,
or both drugs every 2-3 days via i.p. injection for a total of 6 injections. Sabutoclax or
Minocycline alone did not significantly affect tumor growth. The combination of drugs,
however, significantly inhibited tumor growth as compared to controls (Fig. 26).
Immunohistochemistry of tumor sections demonstrated decreased staining for PCNA
and pStat3 in combination-treated tumors (Fig. 27-28).
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Figure 25: KPC tumors express Mcl-1 and KPC cell lines show sensitivity to
Sabutoclax and Minocycline. Tumors from Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt and Pdx1-Cre/K-rasLSL-G12D/p53flox/flox mice overexpress Mcl-1 and show sensitivity to Sabutoclax
and Minocycline. (A) IHC for Mcl-1 in sections of pancreas from control, Pdx-1-Cre/KrasLSL-G12D/p53flox/wt and Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox mice. (B) Western blotting of
whole cell lysates for PARP 48 post treatment in cell lines derived from Pdx-1-Cre/KrasLSL-G12D/p53flox/wt mice. Data representative of three independent experiments.
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Figure 26: Sabutoclax and Minocycline reduce tumor growth in a syngeneic KPC
model. Syngeneic study: Tumor growth kinetics of control Pdx-1-Cre negative/K-rasLSLG12D/p53flox/flox mice bearing subcutaneous Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt–derived
tumors. **p<0.01 as compared to all other groups. n= 5 mice/group.
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Figure 27: Sabutoclax and Minocycline reduce proliferation in a syngeneic KPC
model. IHC for PCNA. Data representative of three independent experiments.
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Figure 28: Sabutoclax and Minocycline reduce Stat3 activation in a syngeneic
KPC model. IHC for pStat3 Y705. Data representative of three independent
experiments.
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Additionally, a survival study was done using KPC mice (Pdx-1-Cre/K-rasLSLG12D/p53flox/flox)

to determine the effects of Sabutoclax and Minocycline.

Mice were

treated with Sabutoclax (1 mg/kg), Minocycline (10 mg/kg), or a combination of both
three times a week via i.p. injection starting at around 1 month of age and continuing
until animals reached a moribund state. Mice receiving combination treatment showed
a significant survival advantage as compared to control mice (Fig. 29). Importantly, no
toxicity was seen from either drug in any of the animal studies conducted.
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Figure 29: Sabutoclax and Minocycline enhance survival in the KPC transgenic
mouse model. Kaplan-Meier survival curve for Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox mice
treated with Sabutoclax and Minocycline. *p=0.001. n = 12 mice (control group); n = 10
mice (Sabutoclax + Minocycline group).
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Discussion:
Pancreatic cancer is one of the most lethal cancers, remaining largely
untreatable. Moreover, advances in therapy have been minimal over the last 15 years,
due in part to the aggressive nature of PDAC and the difficulty in developing selective
and effective therapeutics.

We presently describe an efficacious novel drug

combination for PDAC that uses a new BH3 mimetic and uncovers the hidden
therapeutic potential of Minocycline as an anti-cancer agent.
Considering overexpression of the anti-apoptotic Bcl-2 proteins in PDAC, we
initially evaluated the efficacy of Sabutoclax, a BH3 mimetic that targets these antiapoptotic proteins, inhibiting their function. Sabutoclax was effective as a single agent.
It induced cancer-inhibitory effects in multiple genetically diverse PDAC cell lines.
Potent apoptosis-inducing activity was evident in some PDAC cell lines and in those
that only showed minor increases in death, we found instead a potent cell cycle arrest.
Tumor heterogeneity is a problem manifested to some degree in all cancers, but is
especially relevant in PDAC, contributing to the global resistance seen in this cancer to
conventional chemotherapeutics. A beneficial aspect of Sabutoclax is its anti-cancer
activity in multiple PDAC cell lines, irrespective of genetic background.
Despite the potential of Sabutoclax as a single-agent, there is a pressing need
for combination therapy in the clinical setting.

Cancer is an adaptive disease and

effectively combatting it requires a multifaceted approach. Because of this, we sought
to find a second drug that would potentially synergize with Sabutoclax to further
promote its clinical applicability. We focused on the antibiotic, Minocycline, which has a
small literature base supporting a novel role for this drug in the field of cancer (111-
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115). Despite these reports, translational cancer research using tetracyclines never
expanded as only minor efficacy was evident with these drugs.

In addition to its

classical role as an antibiotic, Minocycline has also been studied extensively as a
neuroprotective agent. Zhu, et. al. showed that this neuroprotection develops, in part,
through the inhibition of caspase-9 and caspase-3 activation after exposure to deathinducing stimuli due to the inhibition of cytochrome c release from mitochondria (118).
Minocycline has also been shown to lead to increases in the expression of antiapoptotic Bcl-2 proteins like Bcl-2 (116,117). We hypothesized that these properties
might actually mask the true potential of Minocycline as a cancer therapeutic and
contribute to the disappointing results seen in the past. However, we hypothesized that
these properties might make it an ideal combination partner for Sabutoclax. Sabutoclax
works by directly acting at the level of the mitochondria, specifically inducing apoptosis
driven by cytochrome c release. In combination with Sabutoclax, the block on apoptosis
in cells treated with Minocycline may be released, thereby leading to synergistic anticancer properties.
Our study has shown that Sabutoclax plus Minocycline is exceptionally effective
against pancreatic cancer (Fig. 30). Subtoxic individual doses of each drug produced a
dramatic synergistic cytotoxic effect.

Furthermore, we found that this combination

resulted in a loss of Stat3 activation. Reintroduction of a constitutively active Stat3
mutant into cells rendered them resistant to the combination of Sabutoclax and
Minocycline. This combination shows promise in vivo using multiple mouse models,
both immune-compromised and immune-competent transgenic models of PDAC,
showing significant anti-cancer activity without any signs of gross toxicities.
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In summary, we describe an innovative combinatorial therapeutic approach with
remarkable activity against pancreatic cancer cells in vitro and in vivo in three animal
PDAC models. Considering the paucity of effective therapies for PDAC, it is clear that
new approaches are mandatory to impact clinically on this invariably fatal cancer. The
ability to target the Bcl-2 family for inactivation, using Sabutoclax, and combining this
with a simple synthetic tetracycline antibiotic, such as Minocycline, opens up new areas
of research with the potential to lead to an effective therapy for pancreatic cancer.
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Figure 30: Overview model showing therapeutic effects of Sabutoclax and
Minocycline in PDAC.
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Chapter III: Gemcitabine Chemotherapy Modification for the
Treatment of Pancreatic Cancer

Introduction:
Pancreatic cancer is an extremely deadly disease, with a 5-year survival rate of
less than 5%. Most tumors are either locally advanced or metastasized at the time of
diagnosis and, intrinsically, this cancer is extremely resistant to chemotherapy and
radiation.

Currently, first line treatment for pancreatic cancer consists of surgical

resection, if possible, and a subsequent course of chemotherapy. This chemotherapy
usually consists of treatment with Gemcitabine (2).
In 1997, Burris, et al. published a clinical study comparing Gemcitabine to 5Fluoruracil for the treatment of pancreatic cancer. In this study, 126 patients were
enrolled with 63 per treatment group. 23.8% of patients showed clinical benefit with
Gemcitabine, as compared to only 4.8% of 5-FU-treated patients. The median survival
was shown to be 5.65 months for Gemcitabine and 4.41 months for 5-FU. Finally, 18%
of patients treated with Gemcitabine were alive at 12-month time point, while survival at
this time point for patients treated with 5-FU was only 2% (3). This trial helped
encourage the FDA to approve Gemcitabine for the treatment of pancreatic cancer in
1998. Gemcitabine is currently a standard treatment used for patients with pancreatic
cancer. Despite this, the drug only provides minimal benefit to patients.
Gemcitabine’s cytotoxic effects are due to its ability to act as a pyrimidine analog.
Gemcitabine triphosphate acts as an analog for deoxycytidine triphosphate, which
allows it to be incorporated into DNA during replication.
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After Gemcitabine is

incorporated, another nucleotide may be added to the chain, but inhibition of chain
elongation subsequently occurs. DNA damage repair is not able to remove the drug
and, consequently, apoptosis occurs (134).
Gemcitabine enters the cell through multiple cell membrane transporters, though
the sodium-independent transporter, hENT1, has been shown to preferentially transport
Gemcitabine (134). Though there are multiple mechanisms of Gemcitabine resistance,
one important mechanism revolves around expression of this protein. Giovannetti, et al.
showed that patients with tumors that express high amounts of hENT1 have a greater
survival advantage with Gemcitabine treatment as compared to those with lower hENT1
expression (Giovannetti, et al. 2006). Patients with higher hENT1 expression have
tumors that can more readily take up Gemcitabine, leading to an increased clinical
benefit.

However, in many tumors, low expression of Gemcitabine transporters

translates to a need for the drug to be administered frequently and at high doses, two
things that can add significantly to drug toxicity.
Toxicity is a major issue with many chemotherapeutic agents and, as a result, the
creation of more targeted therapies that have a lower risk of toxicity has become an
attractive

strategy

in

developing

cancer

therapeutics.

Many

conventional

chemotherapeutic drugs work well in killing cells, but because they also target normal
cells, often lead to high levels of toxicity. Targeted therapies focus on attacking cancer
cells specifically and sparing normal cells to reduce ill side effects.

One specific

strategy of targeted therapy involves modifying currently used drugs to make them
cancer specific. This often involves identifying a biomarker on cancer cells that the
modified drug can target. One such target is the Ephrin receptor.
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Ephrin receptors are a family of tyrosine kinase receptors involved in neuronal
connectivity, blood vessel development, and cell-cell interactions. EphA2 was identified
in 1990 and is expressed in the majority of epithelial cells. In cancer cells, EphA2 is
highly overexpressed and encourages communication not only between individual
cancer cells, but also between cancer cells and surrounding stromal or vascular cells.
EphA2 overexpression also correlates with poor prognosis in patients. Despite EphA2
overexpression, expression of EphrinA1, its ligand, often remains normal even in a
cancerous state. This can lead to accumulation of unactivated EphA2 and subsequent
oncogenic activity (135).
Peptides have been created that, similar to the natural ligand for this receptor,
selectively bind EphA2 and cause receptor activation and internalization.

These

peptides are linked to commonly used chemotherapeutic drugs and act as a specific
delivery strategy for these drugs to tumor cells. Once the receptor is activated, the
peptide and its attached drug are internalized into a lysosome, where the peptide is
degraded and the drug is free to exert its toxic effects on the cell (136). Previous
studies have shown that Paclitaxel conjugated with these peptides shows increased
efficacy in prostate and renal cancers (137).
Gemcitabine, though the current first-line treatment for pancreatic cancer, does
not offer a great therapeutic benefit to patients. This study aims to study a modified
version of Gemcitabine as an alternate to the traditional drug. This modified drug, YNHGemcitabine, consists of the drug with a peptide attached (YNH). This peptide was
designed to specifically bind to the EphrinA2 receptor, which is overexpressed on
pancreatic cancer cells.

The result of this is that the attached Gemcitabine gets
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internalized into the cell via EphA2, bypassing its normal mechanism of cellular entry.
We believe that this will allow a greater amount of Gemcitabine to enter the pancreatic
cancer cell and, ultimately, show greater efficacy in vivo as compared to traditional
Gemcitabine alone.
To expand these studies, we also evaluated 123B9, a newer derivative of the
previously developed YNH family of compounds. Though the YNH compounds showed
good efficacy, the terminal tyrosine of YNH could be degraded by aminopeptidases in
the blood, which limited its half-life. 123B9 contains a synthetic tyrosine that is resistant
to aminopeptidase degradation, leading to a significantly longer half-life in blood and,
hopefully, greater efficacy as well. Due to the recent approval of Gemcitabine and
Abraxane as first-line therapy for metastatic pancreatic cancer, we evaluated 123B9Paclitaxel and Gemcitabine. Additional studies evaluating 123B9-Gemcitabine versus
Gemcitabine in pancreatic cancer are currently in progress.
Materials and Methods:

Human Cell Lines
MIA PaCa-2, PANC-1, BxPC-3, and AsPC-1 cells were all obtained from the American
Type Culture Collection (ATCC). LT2 cells were purchased from Millipore. MIA PaCa-2
and PANC-1 were maintained in DMEM plus 10% FBS. BxPC-3 and AsPC-1 cells were
maintained in RPMI plus 10% FBS. LT2 cells were maintained with media according to
distributor’s instructions.

Cell lines were expanded and cryopreserved at early

passages and new vials were thawed out and used for experiments approximately
every 3 months.
89

Drugs and Drug Administration
Gemcitabine,

YDH-Gemcitabine,

YNH-Gemcitabine,

Paclitaxel,

123B9,

123B9-

Paclitaxel and 123B9-Gemcitabine were produced by Dr. Maurizio Pellecchia (SanfordBurnham Institute, La Jolla, CA). For biological studies, all drugs were diluted in 10%
Tween80, 10% DMSO, and 80% PBS.

Western Blotting
5 x 105 cells were plated in 6-cm dishes and treated as described. After 48 hours, whole
cell lysates were prepared and western blotting analysis was carried out as previously
described (120). Primary antibodies used for these studies were EphrinA2 (1:1,000, Cell
Signaling) and EF1-α (1:5,000, Sigma).

Subcutaneous Xenograft Studies
5 x 106 MIA PaCa-2-luciferase cells were used to establish bilateral subcutaneous
tumors on the flanks of 8-10 week old male athymic nude mice. Studies were done as
previously described (109). Treatment began when tumors reached ~100-mm3. All
drugs were administered by tail vein injection twice per week for 4 weeks, a total of 8
injections. Gemcitabine was given at a dose of 10 mg/kg and all Gemcitabine
derivatives were given at equimolar doses to 10mg/kg Gemcitabine, also via tail vein
injection. PTX was given at a dose of 2.5mg/kg. All 123B9 compounds were given in
equimolar doses to PTX. BLI was done at the beginning and end of the study. Tumors
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were measured twice per week using calipers.

Tumors were fixed in formalin,

embedded in paraffin, and sectioned for staining.

Survival Study
After their last injection, mice were kept for 1 additional week to monitor tumor growth
and imaged at the end of this week. The mice were then kept to monitor for the effects
of treatment on survival. Mice were kept until reaching a moribund status or until tumors
reached a combined volume of 2000mm3, whichever came first.

They were then

sacrificed at this time.

BLI
During imaging, mice were placed in the imaging chamber and maintained with 2%
isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse.
Anesthetized mice were injected IP with 150 mg/kg body weight D-Luciferin (Xenogen
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a
charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS)
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA).

Statistical Analysis
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For in vivo studies, data shown are the mean + 95% confidence interval. Significance
was determined using the Student’s t-test.

p<0.05 was considered statistically

significant.
Results:

YNH-Gemcitabine shows greater efficacy in vivo compared to Gemcitabine

MIA-PaCa-2-luc cells were used to create bilateral subcutaneous xenografts in
athymic mice. Western blot data shows that this pancreatic cancer cell line highly
expresses EphA2 (Figure 31). Cells were injected into each flank and then allowed to
grow for approximately 1 week. At this point, mice were imaged using BLI and
treatment was subsequently initiated. Mice were divided into 4 groups (PBS,
Gemcitabine, YDH-Gemcitabine, YNH-Gemcitabine) with 9 mice/group. YDHGemcitabine is a scrambled control, where the peptide attached to Gemcitabine should
not be specific for EphA2 and, therefore, should not bind to the receptor. Animals were
treated 2x/week via tail vein injection for 4 weeks. A dose of 10mg/kg Gemcitabine was
used along with equimolar doses of YDH-Gemcitabine and YNH-Gemcitabine. At the
end of 4 weeks, animals were again imaged and treatment was ended.
As expected, YDH-Gemcitabine did not have significant effects on tumor growth.
Gemcitabine had a modest effect on tumor growth, though YNH-Gemcitabine showed
the greatest inhibition of tumor growth of all groups evaluated (Fig. 32). This can be
observed both through tumor measurement and by BLI (Fig. 33). No negative side
effects of the drugs were observed and the mouse weight remained consistent

92

throughout the study (data not shown). 3 animals per group were sacrificed at the end
of this study and tumors were excised and fixed in formalin for further study.
To determine whether YNH-Gemcitabine also gave a survival advantage,
remaining mice were not sacrificed at the end of the experiment, but rather when their
individual tumor burden approached 2000mm3. YNH-Gemcitabine gave mice a
significant survival advantage over other treatment groups (Fig. 34).
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Figure 31: Pancreatic Cancer cells express EphA2. Western blotting of normal
pancreatic fibroblasts and pancreatic cancer cells.
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Figure 32 : YNH-Gemcitabine inhibits tumor growth in vivo to a greater extent as
compared to Gemcitabine. Tumor volume as calculated by caliper tumor
measurement. *p < 0.05;** p<0.01. n=9 mice/group
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Figure 33 : YNH-Gemcitabine inhibits tumor growth in vivo to a greater extent as
compared to Gemcitabine. Bioluminescent tumor images at Day 34. Exposure time =
0.5 seconds
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*

Figure 34: YNH-Gemcitabine prolongs in a xenograft model of pancreatic cancer.
Kaplan-Meier curve showing survival in days. *p < 0.05.
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123B9-Paclitaxel and Gemcitabine show combination effects in pancreatic cancer
in vivo

MIA-PaCa-2-luc cells were used to create bilateral subcutaneous xenografts in
athymic mice. Cells were injected bilaterally into the flanks and then allowed to grow for
approximately 1 week. At this point, mice were imaged using BLI and then treatment
was initiated. Mice were divided into 8 groups (Control, Gemcitabine, PTX, Gem+PTX,
123B9-PTX, 123B9+PTX, 123B9-PTX+Gem, 123B9+PTX+Gem) with 5 mice/group.
Animals were treated 2x/week via tail vein injection for 4 weeks. A dose of 10mg/kg
Gemcitabine, 2.5mg/kg PTX, and an equimolar dose of the 123B9 compounds were
used. Tumors were measured with calipers twice a week. At the end of 4 weeks,
animals were again imaged and treatment was stopped. No negative side effects from
any of the compounds used were observed and the mouse weight remained consistent
throughout the study (data not shown).
As expected, Gemcitabine or PTX treatment alone did not have a significant
effect on tumor growth, but the combination of these two drugs did significantly inhibit
tumor growth (Fig. 35). Additionally, both 123B9-PTX and 123B9+PTX showed greater
inhibition of tumor growth as compared to PTX (Fig. 36). The addition of Gemcitabine
to these groups further suppressed tumor growth. Mice that were treated with
123B9+PTX+Gem showed the greatest inhibition of tumor growth (Fig. 37). Tumors in
this group were significantly smaller as compared to 123B9+PTX, PTX, Gem, and
Control groups.

98

Figure 35: Gemcitabine (Gem) and Paclitaxel (PTX) inhibit tumor growth in vivo
to a greater extent than either single drug. Tumor volume as calculated by caliper
tumor measurement. Asterisks show significance between the Gem+PTX group and
Control, Gem, and PTX groups. *p<0.05; **p<0.01. n=5 mice/group
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Figure 36: 123B9-PTX inhibits tumor growth in vivo to a greater extent than PTX.
Tumor volume as calculated by caliper tumor measurement. Asterisks show
significance between the 123B9-PTX group and both the PTX and Control groups.
*p<0.05; **p<0.01 n=5 mice/group
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Figure 37: 123B9+PTX+Gem inhibit tumor growth in vivo to a greater extent than
other treatment combinations. Tumor volume as calculated by caliper tumor
measurement. Asterisks show significance between the 123B9+PTX+Gem group and
Control, Gem, PTX, Gem+PTX, and 123B9+PTX groups. *p<0.05. n=5 mice/group
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Discussion
Though not overly efficacious, chemotherapy remains the mainstay of pancreatic
cancer therapy. There is a vital need to develop novel therapies that provide greater
clinical benefit to patients. This study evaluated modifications of both Gemcitabine and
Paclitaxel against pancreatic cancer. The strategy involved in these modifications
revolved around developing conjugated drugs that are capable of specifically targeting
the EphA2 receptor that is overexpressed on the surface of pancreatic cancer cells.
Initial studies used Gemcitabine linked to the YNH peptide, which showed encouraging
results. This modified drug show greater tumor growth inhibition and prolonged survival
in a xenograft model of pancreatic cancer.
However, despite these results, the YNH was found to have less than optimal
plasma stability. The terminal tyrosine of this peptide, which is essential to specific
EphA2 binding, was shown to be susceptible to aminopeptidases in the blood, leading
to degradation. This resulted in a half-life of only a few minutes. A new peptide was
subsequently created, 123B9, which replaced the terminal tyrosine with a synthetic
tyrosine. This new amino acid is resistant to aminopeptidase degradation while still
retaining EphA2 specificity. This translates into an increased drug half-life of
approximately 4 hours.
Paclitaxel is a commonly used chemotherapeutic drug most often used in breast,
lung, ovarian, and AIDS-related sarcomas, though it is studied and sometimes used in
combination in other cancer types as well. Paclitaxel is a microtubule inhibitor and acts
to stabilize polymerized microtubules. Consequently, cells get stuck in the G2 and M
phases of the cell cycle. Solubility is a major issue with this drug. It must be
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administered in a solution with Cremophor and dehydrated ethanol. These vehicles can
have toxic effects on their own and have led to the inability to use higher doses of this
chemotherapeutic drug in patients. Furthermore, Cremophor-bound paclitaxel has a
tendency to form micelles that trap the drug in the center, limiting its efficacy (138).
Recently a novel formulation of Paclitaxel has been developed in which the drug
is bound to albumin (nab-Paclitaxel). High-pressure homogenization is used to combine
albumin and paclitaxel. Once injected, the drug is free to bind/unbind albumin or other
molecules in the blood freely. This results in more unbound drug in the circulation as
compared to Cremophor-bound drug. However, the nab-paclitaxel that is bound tends
to be bound to albumin, which helps to facilitate its entry into tumor cells. NabPaclitaxel can use normal albumin transport mechanisms to gain entry. Also, some
albumin-binding proteins, such as SPARC, show high prevalence in the tumor
microenvironment. Whether or not this has clinical significance is still unclear (138). In
mouse studies, xenografted pancreatic tumors were found to have a 2.8 fold increase in
intratumoral Gemcitabine concentration when the drug was administered in combination
with nab-Paclitaxel. They hypothesized that this may be due to nab-Paclitaxel-induced
disruption of the stroma (139).
A Phase 3 clinical study in patients with metastatic pancreatic cancer evaluated nabPaclitaxel + Gemcitabine versus Gemcitabine alone in a total of 861 patients. The
median survival was 8.5 months in the nab-paclitaxel + Gemcitabine group vs. 6.7
months in the Gemcitabine group. The survival rate at 1 year was 35% vs 22%; 9% vs
4% at 2 years. The response rate was 23% for combination group and 7% for
Gemcitabine alone. Toxicities included neutropenia, fatigue, and neuropathy (140).
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These results encouraged the FDA to approve the combination of Gemcitabine and
nab-Paclitaxel (Gem-Abraxane) for metastatic pancreatic cancer.
In conclusion, these novel Ephrin-binding peptides represent an exciting new
strategy in cancer drug development. Of significant interest is that this technique is not
limited to a single drug, but rather can be adapted to almost any drug, either by linking
the drug of interest to a peptide or by using it in combination with the peptide. We
found in our studies with Paclitaxel that 123B9 showed greater tumor inhibition,
presumably by helping to facilitate drug entry into cancer cells, even when it wasn’t
actually linked with Paclitaxel. In fact, when 123B9 was administered in conjunction
with chemotherapy (Gemcitabine and Paclitaxel), but not actually as part of a modified
drug, we saw the greatest efficacy. We believe that this may be due to 123B9
encouraging entry of both Paclitaxel and Gemcitabine. Overall, these studies provide
encouraging evidence that modifications of standard chemotherapeutic agents have the
potential to improve clinical outcome in pancreatic cancer patients.
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Chapter 4: Characterization of a novel double transgenic pancreatic
adenocarcinoma mouse, ‘PanMetView (PMV) Mouse’, to non-invasively monitor
tumor development and progression.

Introduction
Pancreatic cancer is an extremely deadly disease that lacks efficacious
therapeutic options (1). There is a dire need to develop novel therapies for targeting this
cancer. Translational research has focused on many strategies to target this cancer
(141-145), but the study of such strategies is often impeded by the lack of appropriate
preclinical models to validate efficacy. The creation of effective drugs or therapeutic
strategies is a rigorous process that requires not only an understanding of the
mechanism of action of a new drug, but also the ability to stringently test compounds in
appropriate in vitro and in vivo settings. In vitro studies are fairly straightforward, as a
variety of human pancreatic cancer cell lines have been established and are available to
test experimental drugs (146). Testing new drugs in vivo, however, can be a daunting
challenge if one does not have an appropriate preclinical model that recapitulates
pancreatic cancer development and disease progression. Currently, there are a number
of transgenic mouse models of pancreatic cancer that have been developed. They vary
in a variety of ways, including the histological subtype of tumor developed, tumor
latency, and the absence or presence of metastases (147,148). However, one missing
component of all of these models is an efficient and simple global method to temporally
monitor tumor development and growth. To perform sophisticated preclinical animal
studies, one must be able to monitor tumor kinetics in a quantifiable way and use this
strategy to define efficacy of newly developed therapies. Doing so in a non-invasive
manner without having to sacrifice the mouse is particularly difficult and defining
105

approaches to obviate this problem will be transformative for preclinical testing of
therapies.
Bioluminescence imaging (BLI) is an optical imaging technique that is relatively
inexpensive, user-friendly, and has wide-spectrum applicability. It is based on the ability
of a cell that expresses luciferase to convert luciferin into oxyluciferin, which results in
the release of photons that can be captured and processed into an image (149,150).
Traditionally, this imaging modality has been used in xenograft studies, where cells that
are engineered to express luciferase are injected subcutaneously or orthotopically into
mice to create a tumor model with imaging capabilities. We are pioneering a strategy in
which we can use BLI to image pancreatic tumors in the widely used pancreatic ductal
adenocarcinoma (KPC) transgenic mouse model, or in principle any other solid tumor
transgenic mouse model.
Bioluminescence imaging (BLI) has been transformative for animal tumor studies
permitting live non-invasive in vivo imaging to monitor tumor growth and progression
using xenograft, orthotopic and metastasis models (149-154). For optimizing this type of
imaging for transgenic animals, cancerous cells in the transgenic animals need to
express a reporter gene, such as luciferase, under the control of a cancer-specific
(cancer-selective) promoter. In previous collaborative studies with Dr. Martin G. Pomper
(Johns Hopkins University) we demonstrated the utility of a reporter gene expressed
under the control of a cancer-specific promoter, progression elevated gene-3 (PEGProm), to image metastases (153) and study tumor progression.
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CCN1 is a member of a large family of integrin-binding proteins that affects
multiple signal transduction pathways in cells (155,156). In cancer, integrin-binding
proteins are often dysregulated and can lead to changes in cell migration, adhesion,
angiogenesis, and tumor growth. In pancreatic cancer, CCN1 mRNA and protein are
elevated in tumor specimens and established pancreatic tumor cell lines (157). CCN1 is
critical for EMT in this cancer type as well as for maintenance of stemness and
aggressive behavior, with more aggressive cell lines expressing higher levels of CCN1
(158). These pro-tumorigenic properties result in part through signaling via the Sonic
hedgehog pathway (159,160). Silencing of CCN1 has also been shown to mitigate
some of CCN1’s pro-cancer properties (158). Based on the cancer-selectivity of CCN1,
we hypothesized that a CCN1-promoter-driven construct would be amenable for
imaging tumors and metastases in vivo, similar to what we found with the PEG-PromLuc-PEI construct (154). This possibility was verified using a CCN1-Prom-Luc-PEI
construct, which when administered intravenously to nude mice containing primary and
metastatic tumors was able to image these tumors/metastases (data not shown).
The PDAC KPC transgenic mouse model, Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt,
has been used to study pancreatic cancer development and progression as well as
therapeutic approaches for inhibiting these processes (128-132). As with all cancers,
there is a multitude of genetic changes observed in PDAC that contribute to its
development and progression. Activating K-ras mutations are found in over 90% of
pancreatic cancers (1), making it a highly active contributor to the tumorigenic state.
There is also a variety of tumor suppressors lost in high frequency in this disease, p53
being one of them. This important gene is either deleted or functionally inactivated in
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approximately 50-75% of PDAC (1). The KPC model of PDAC, which is broadly used in
the pancreatic cancer field, mimics these human genetic changes in the mouse. A
mutated form of K-ras, rendering it constitutively active (K-rasG12D), is introduced into the
mouse with a Lox-Stop-Lox sequence located transcriptionally upstream (K-rasLSL-G12D).
p53 alleles are floxed in these animals as well, either one or both alleles (p53 fl/wt or
p53fl/fl). Cre-mediated recombination results in the removal of the stop codon preceding
the mutant K-ras and expression of this new genetic element, giving the tissue continual
K-ras signaling. Additionally, Cre will remove one or both alleles of p53, resulting in full
or partial loss of function of this critical tumor suppressor. Cre is introduced into the
pancreas through the transcriptional control of a pancreatic-specific promoter, Pdx-1.
When both alleles of p53 are deleted, tumors develop very rapidly and most animals do
not live past 2 months of age, with a tumor latency of around 6 weeks. Animals that still
retain one functioning p53 allele show longer tumor latency of around 21 weeks. This
longer survival permits additional time to therapeutically intervene. p53 null animals,
however, have more aggressive disease and can be useful for certain studies. As seen
in human PDAC, this disease initially develops as a series of pre-invasive lesions, or
Pancreatic Intraepithelial Neoplasms (PanINs) before eventually becoming an invasive
cancer. The tumors show both local invasion and micrometastasis (133).
We hypothesized that crossing these animals to a mouse that expresses
luciferase under the control of a cancer-selective promoter, CCN1, would result in a
mouse in which CCN1 would be transcriptionally activated in conjunction with tumor
development in the pancreas and that the tumor cells would subsequently express
luciferase, allowing them to be easily imaged via BLI (Fig. 38). We also aim to show that
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this model is not only capable of detecting primary tumor development through BLI, but
that metastatic lesions may also be visualized through this method. This is a significant
advantage over traditional imaging methods, where the detection of metastasis is very
difficult. These studies in general are highly significant, as they will provide a new
platform for developing and using transgenic mice to study pancreatic, and theoretically
other cancers, development and progression.
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Figure 38: Development strategy for the PMV Mouse
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Methods
Characterization of ‘PanMetView’ (PMV) Mice
Useful progeny PMV mice with the following genotypes were followed temporally by
BLI: animals positive for the activating K-ras mutation, having either one or both alleles
of p53 lost, positive for Pdx-1-Cre (which is responsible for the appropriate K-ras and
p53 genetic changes), and also expressing CCN1-luc. We evaluated approximately 1520 mice. Mice were started on an imaging protocol beginning post-weaning, at around 4
weeks of age. Animals were imaged using BLI one time per week and any signal on
these images was quantified using Living Image software. Weekly imaging was followed
over time and tumor kinetic graphs for each mouse based on these imaging studies
were created. These mice were followed by BLI until they reached a moribund status.
At this point, the mice were sacrificed and imaging done at different points throughout
the necropsy to determine the origin of any signal seen in the animal.

BLI of PMV Mice
During imaging, PMV mice were placed in the imaging chamber and maintained with
2% isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse.
Anesthetized mice were injected IP with 150 mg/kg body weight D-Luciferin (Xenogen
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a
charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS)
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA). The positive signal from
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background-subtracted images was analyzed by Living Image software for integrated
density.
Analysis of tumor tissues
Criteria for euthanasia included loss of body mass, abdominal bloating and/or lack of
grooming behavior. Once mice reach a point where sacrifice is required, the animals
were necropsied post-imaging. A second set of images was taken of individual organs
to confirm the origin of the signal seen in the first set of images of the live animal.
Tumor tissue was preserved in neutral buffered formalin and formalin fixed and
sectioned for further evaluation.
Immunohistochemistry
Tumors were fixed in formalin, embedded in paraffin, and sectioned for staining.
Staining was done as previously described (122) with anti-CCN1 (1:100, Abcam) per
the manufacturer’s instructions.

Results
KPC mouse tumors express CCN1
The KPC (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mouse is extensively used as a
representative model for PDAC development and progression, and for therapeutic
studies (128-132). This animal spontaneously develops precursor pancreatic lesions,
PanINs, which progress and eventually develop into invasive disease. The model
recapitulates the human condition, in which animals remain symptomatically unaffected
by their disease until it is at a late stage of development. Tumors form as a result of
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activated K-ras and functional loss of p53 in the pancreas, genetic changes also seen in
a high percentage of human tumors.

Histological analysis shows extensive local

invasion as well as metastasis in a subset of animals (133). Immunohistochemistry
(IHC) was used to monitor CCN1 expression in KPC mouse pancreatic tissue from
control, p53+/-, and p53-/- animals. Control animals had limited basal CCN1 expression,
with the exception of the islets of Langerhans, which showed mild CCN1 expression.
Mice with p53+/- tumors had increased CCN1 expression and mice with p53-/- tumors,
which are more aggressive, showed very high CCN1 expression (Fig. 39). To
summarize,

CCN1

expression

correlates with

both

PDAC development

and

aggressiveness in the KPC mouse model. This data supports double transgenic GEMs
that incorporate the CCN1-Luc promoter to identify tumors and metastases in the KPC
PDAC mouse.
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Figure 39: KPC mouse tumors highly express CCN1. CCN1 expression by IHC in
sections of normal pancreas or pancreatic tumor from control and transgenic KPC mice.
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CCN1-luc-KPC mice can monitor pancreatic tumor growth in vivo
CCN1-luc mice were crossed with KPC mice to generated PanMetView (PMV)
mice and several PMV mice have now been evaluated. After weaning, the mice were
started on an imaging protocol, in which they were imaged by BLI one time per week.
We evaluated both p53wt/fl and p53fl/fl mice. This allowed us to study a number of
additional factors, such as metastases. As has been previously shown (133), a portion
of p53wt/fl mice will show metastases as well as local invasion. Most p53 fl/fl mice though,
because of the aggressive nature of their disease and their short lifespan, do not show
distant metastasis, though evidence of local invasion is still demonstrated (133).
PMV Mouse #41 (p53fl/fl): This mouse was imaged twice before it reached a moribund
state requiring sacrifice. This animal showed strong abdominal signals, representing
underlying tumor once the animal was necropsied. As CCN1 is expressed in the testes,
a signal in the testes in this animal was evident (Fig. 40). The strong signal from the
testes often masks the signal from the pancreas. To overcome this issue, we covered
the testes with dark paper blocking the signal, thereby allowing any signal originating in
the pancreas or other CCN1-expressing tumor cells to be identified (Fig. 40). During
necropsy, individual organs were imaged to determine the signal source. As in the
intact animal, the testes masked tumor expression, though when they were removed,
the signal was clearly seen in the remaining organs. Most of the signal came from the
pancreatic tumor, though signal was also detected in the spleen (which was encased in
tumor upon opening the animal) and in the lung (Fig. 40B). Lung tissue will be analyzed
to determine the presence of lung metastases.
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A

B

Figure 40: Characterization of PMV Mouse #41 (p53fl/fl). (A) Upper panel: intact
mouse showing amplification of abdominal signal when testes are covered. Lower
panel: exposed abdominal cavity showing actual pancreatic tumor and amplification of
signal from that tumor following testes coverage. (B) Individual organ post necropsy of
Mouse #41 showing specificity of signal
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PMV Mouse #51 (p53fl/fl): This animal also showed strong abdominal signals, as well
as signals from the testes (Fig. 41). This mouse was imaged for four weeks before
sacrifice. Upon necropsy, a signal was also detected in the spleen and lung (Fig. 41B).
This mouse had a large pancreatic tumor that displayed a strong and specific signal.

PMV Mouse #48 (p53fl/wt): This animal still has one functioning allele of p53, which
results in a mouse with a longer tumor latency. Because of this, we were able to gather
imaging data on this animal for approximately 2 months. The data show a clear increase
in tumor growth that can be observed both through BLI and the quantification of these
images (Fig. 42).

PMV Mouse #225 (p53fl/fl): Imaging of this mouse showed evidence of a pancreatic
tumor as well as potential lung metastasis. Individual organ imaging supported this
(Fig.43).

PMV Mouse #247 (p53fl/fl): Similar to previous mice evaluated, this mouse showed
increasing signal over time, which paralleled its underlying tumor development.
Evaluation of organs after sacrifice showed tumor specificity. This mouse also showed
evidence of metastasis in the lung as well as in the area ventral to the
esophagus/trachea. This latter region is atypical for this model (Fig 44).
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A

B

Figure 41: Characterization of PMV Mouse #51 (p53fl/fl).
(A) BLI images and
quantification. (B) BLI of organs post necropsy. Exposure = 10 seconds
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Figure 42: Characterization of PMV Mouse #48 (p53fl/wt). BLI images and
quantification. Exposure = 15 seconds.
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A

B

Figure 43: Characterization of PMV Mouse #225 (p53fl/fl). (A) BLI images. (B) BLI
images of organs post-necropsy.
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A

B

Figure 44: Characterization of PMV Mouse #247 (p53fl/fl).
quantification. (B) BLI images of organs post-necropsy.
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(A) BLI images and

PMV Mouse 271 (p53fl/fl) – female: Unlike the testes of male mice, female PMV mice
do not show any strong non-specific signal. The increasing signal seen is most likely
indicative of underlying tumor (Fig. 45).

PMV Mouse 261 (p53fl/fl) – female: This mouse did not show significant non-specific
signal throughout imaging. Upon necropsy, pancreatic tumor and lung showed
expression, as well as minor expression in the reproductive tract. However, though
there is some background signal in the reproductive tract, removing these organs do not
significantly enhance the signal in the pancreas and lung, which supports that the signal
is only mild and not affecting the ability to detect the pancreatic tumor (Fig. 46).

PMV Mouse 249 (p53fl/fl) – female: This mouse showed specific signal in the
pancreas/pancreatic tumor. There does not appear to be any evidence of metastasis in
this animal – the lungs were negative for expression (Fig. 47).
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Figure 45: Characterization of PMV Mouse #271 (p53fl/fl)(female). BLI images.
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A

B

Figure 46: Characterization of PMV Mouse #261 (p53fl/fl)(female).
(B) BLI images of organs post-necropsy.
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(A) BLI images.

A

B

Figure 47: Characterization of PMV Mouse #249 (p53fl/fl)(female).
(B) Imaging of opened abdominal cavity and organs post necropsy.
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(A) BLI images.

A PMV pancreatic tumor-derived cell line retains luciferase expression in vitro

A cell line was established in vitro from a pancreatic tumor that developed in
PMV Mouse #48. After being established in culture, cells (1 x 106) were injected
bilaterally into the flanks of three athymic nude mice. Imaging at 10 days post-injection
showed that these cells retained luciferase activity. Luciferase expression was detected
by BLI in these tumors (Fig. 48). The tumors developed very rapidly and showed a more
aggressive phenotype as compared to human pancreatic cancer cell lines similarly
injected into nude mice (i.e., MIA-PaCa-2 and PANC-1 cells) (data not shown). These
cells were also injected intraperitoneally into immune-competent Pdx-1-Cre-negative/KrasLSL-G12D/p53 mice, where they showed luciferase expression approximately 1 week
after injection (Fig. 48). This last set of conditions was also repeated with bilateral flank
injections. These mice form rapid tumors that can be imaged by BLI and make for a
very useful syngeneic mouse model (Fig. 48).
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Figure 48: PMV-derived cells retain luciferase activity in vitro and when
reintroduced in vivo
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Discussion

The KPC model (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) combines a mutated form of
K-ras with loss of either one or both alleles of p53 specifically in pancreatic tissue, which
is accomplished through the use of a pancreatic specific promoter, Pdx-1. The result is
a mouse that develops spontaneous pancreatic ductal adenocarcinoma (PDAC) at
approximately 21 weeks of age (133).
Current studies utilizing the KPC model highlight the need for improved
monitoring of tumors. Many studies either wait until an animal is sacrificed to collect
data on therapeutic efficacy (130,132) or use more sophisticated imaging techniques
that require additional training and cost (129,131). To enhance the utility of the KPC
transgenic mouse model we developed CCN1-Prom-Luc (CCN1-Luc) transgenic mice,
which display de novo Luciferase expression in the testes, but no other organ. Crossing
CCN1-Luc mice with PDAC (KPC; Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mice generated
double transgenic mice (CCN1-luc/Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt mice, PanMetView
or PMV). Primary tumors and metastases in PMV mice display luciferase expression as
pancreatic cancers develop and metastasize. Confirming the utility of PMV mice for
detecting and monitoring progression and therapy of pancreatic cancer has the potential
to transform how this PDAC animal model is used to study pancreatic cancer.
Additionally, this approach also holds significant promise as a potentially universal
strategy for converting any transgenic animal into a reporter-driven PanMetView (PMV)
mouse by crossing it with CCN1-Prom-Luc transgenic mice.
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All animals imaged thus far have shown expression in the testes, which was
expected due to CCN1 expression in this organ. The signal in the testes is frequently
strong enough that it overshadows any other signals, which can be problematic.
However, because the anatomical location of this organ is distant from that of the
pancreas, we can use black paper to physically cover parts of the mouse to block such
signals. When one utilizes this approach, non-testes signals intensify. This has been a
useful technique in identifying the presence of pancreatic tumors. Future studies will
include alternate means of genetic and chemical modification to reduce or eliminate this
signal in male animals. In the context of female animals, no non-specific signals are
detected.
As with many transgenic models of human cancer, the KPC models shows great
variability from animal to animal with respect to the precise time of tumor development,
as well as the kinetics of tumor growth. This problem is also seen in the human disease
state. PDAC is a particularly variable cancer, as some patients can survive for longer
periods of time with a high tumor volume, while other patients die with relatively small
tumors. The location of the tumor, as well as the growth parameters and invasive nature
of the tumor, all of which can affect the normal functioning of surrounding organs and
vessels, contributes to this end point. Because of this variability, one cannot make
assumptions on the therapeutic efficacy of a drug based on a group of these mice.
Rather, each mouse needs to be evaluated individually so as to be able to accurately
assess the outcome of therapy on a particular tumor. The ability to generate individual
tumor kinetic curves with the PMV mouse will be a great advantage to developing highly
impactful preclinical studies.
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Our PMV model provides a way of non-invasively monitoring KPC tumor
progression that improves the quality of studies relying on survival and/or post-mortem
evaluation for data. Additionally, our PMV model also provides an imaging strategy that
is relatively inexpensive, easy to use, and has wide levels of applicability, which gives it
advantages over other imaging modalities. Furthermore, the ability to detect metastasis
is possible using the PMV system, which is not a possibility with imaging methods, such
as ultrasound. The PMV model is transformative and can be rapidly used to test for
effective therapies of PDAC in an immune-competent transgenic mouse. Showing the
therapeutic efficacy of a novel drug or compound in immune-competent transgenic preclinical models of disease is critical for developing improved therapies for patients with
PDAC. Our proposed studies will allow for a significant gain in utility of an accepted
PDAC model for the study of pancreatic cancer development, progression and therapy.
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Chapter 5: Summary and Future Perspectives

Despite years of research, pancreatic cancer remains an extremely deadly
disease with very few therapeutic options. The poor prognosis results from both a delay
in diagnosis, due to a lack of telling symptoms, as well as a significant amount of
diverse genetic changes, which contribute to its intrinsic aggressive nature and
resistance to standard therapies. This body of work has focused on exploring novel
avenues of therapeutic targeting in pancreatic cancer. This includes the identification
and targeting of novel targets, the modification of current therapies to improve efficacy,
and the creation of improved methods of studying potential therapies in preclinical work.
Chapter 2 describes this first technique, in which the anti-apoptotic Bcl-2 proteins
were hypothesized to be a potential therapeutic target in pancreatic cancer. Sabutoclax,
a small molecule BH3 mimetic, binds to and inhibits the function of the anti-apoptotic
Bcl-2 proteins.

In this study, we aimed to evaluate the efficacy of Sabutoclax and

Minocycline, a synthetic tetracycline and understudied potential anti-cancer agent in the
treatment of pancreatic cancer. We used a variety of in vitro techniques including
proliferation and cell death assays, cell cycle analysis, and western blotting to
accomplish this in multiple pancreatic cancer cell lines. Several mouse models were
also used to scrutinize these drugs in vivo, including the commonly used KPC mouse
model. Sabutoclax induced growth arrest and apoptosis in pancreatic cancer cells and
synergized with Minocycline. Together, these two drugs showed profound cytotoxicity
that was caspase-dependent and occurred through the mitochondrial pathway of
apoptosis. Furthermore, the toxicity induced by Sabutoclax and Minocycline was reliant
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upon loss of phosphorylated Stat3, with reintroduction of activated Stat3 capable of
rescuing cells from toxicity. In vivo work showed that this combination inhibited tumor
growth in immune-deficient and immune-competent models and prolonged survival in
the KPC transgenic mouse.

In conclusion, Sabutoclax and Minocycline promoted

profound cytotoxicity in pancreatic cancer, both in vitro and in multiple in vivo animal
models providing significant survival benefits. These drugs offer a novel and exciting
direction for developing effective therapeutic options for patients with this devastating
disease.
Chapter 3 introduced

a novel strategy of

taking a commonly used

chemotherapeutic drug, Gemcitabine, and altering it in an attempt to increase efficacy.
Despite being used extensively in the treatment of pancreatic cancer, Gemcitabine
delivers minimal survival results at best. This is partly due to intrinsic cellular resistance
mechanisms that lead to either decreased uptake of the drug, improper metabolism and
utilization, or increased output of the drug. We showed that linking Gemcitabine to a
peptide that specifically targets the EphrinA2 receptor, which is overexpressed on
pancreatic cancer cell surfaces, leads to an increased uptake of the drug through an
alternate delivery mechanism. More recent studies using a synthetic peptide, 123B9,
tethered to Paclitaxel also showed encouraging results, with the drug conjugate
demonstrating better efficacy as compared to Paclitaxel alone. This modified drug also
showed exciting results when used in combination with Gemcitabine. These studies
and this combination in particular are extremely clinically relevant due to the recent
approval of Gemcitabine-Abraxane (nab-Paclitaxel) as the first line treatment for
metastatic pancreatic cancer.

123B9 demonstrates increased plasma stability as
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compared to YNH, which translates to greater clinical potential. We found that in vivo,
these novel drug conjugates inhibit tumor growth and lead to a prolonged survival.
Importantly, the addition of the peptide does not confer any additional toxicity to the
drug and holds significant clinical potential. 123B9-Gemcitabine conjugates have been
made as well and studies with this drug are in progress.
Finally, in Chapter 4 we introduce an exciting and novel preclinical mouse model
that builds off of the existing and commonly used KPC transgenic mouse model of
pancreatic cancer. Though this model accurately recapitulates the human disease,
monitoring tumor development and growth remains a difficult obstacle and hinders the
ability of researchers to perform sophisticated studies with this animal. Many imaging
techniques, such as ultrasound or PET, though useful for monitoring tumor in these
mice, can be expensive, require extensive training, and take significant time. Most
importantly, these methods cannot detect tumor metastasis, an important feature of this
disease.

We hypothesized that crossing KPC mice to a mouse that expresses a

Luciferase reporter gene under the control of a cancer specific promoter, CCN1, would
allow us to create a mouse in which the promoter was turned on during cancer
development in the pancreas and lead to luciferase expression in all transformed cells.
Luciferase expression in vivo can be easily monitored via BLI and provides a rapid
result image that can be easily quantified to follow tumor development. Of significance
is the ability to monitor metastasis in this mouse. As tumor cells express luciferase,
metastatic lesions that would otherwise be too small to see via other imaging modalities
show expression using BLI and provide a novel technique of monitoring the metastatic
process in the KPC model.
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Moving forward, these studies provide important beginnings for novel avenues of
therapeutic exploration in pancreatic cancer.

The Bcl-2 family of proteins is

understudied as a therapeutic target in pancreatic cancer and our data provide solid
evidence that compounds such as Sabutoclax deserve further attention and study.
From a clinical perspective, there is significant potential in targeting Mcl-1 for
suppression. The Bcl-2 anti-apoptotic proteins continue to present roadblocks in the
treatment

of

cancers

when

using

conventional

chemotherapeutics.

overexpression becomes vital to the survival of many types of tumors.

Their
Mcl-1, in

particular, plays a significant role in the ability of cancers not only to survive, but also to
resist treatment with chemotherapy and radiation. In vitro experiments using Mcl-1 ASO
emphasize the anti-tumor potential of targeting Mcl-1 both alone and in combination
with other therapeutic agents.
Developing an optimal cancer therapeutic for any tumor indication is clearly an
imprecise process and very difficult. To achieve this objective, a number of issues must
be considered one of which is the best approach to use. What technique would be most
appropriate to target Mcl-1?

Since the ultimate aim is to develop a viable clinical

therapy, it is important to consider the translational potential of any strategy. Some
strategies, like those that employ ASO, may be very effective in in vitro and preclinical
experimental settings, but are not easily translated into the clinic. In contrast, other
methodologies, like the use of small molecule antagonists, may hold greater potential
for clinical translation if an effective drug level can be attained without unacceptable
toxicity.

Ultimately, the real potential of these compounds may lie in combination

therapies, as we have demonstrated with Sabutoclax and Minocycline.
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Another important consideration in developing an appropriate cancer therapeutic
is the target itself. There is abundant evidence in almost every cancer type that the Bcl2 anti-apoptotic proteins play a significant role to some extent in that cancer’s survival.
Many studies provide evidence that targeting these anti-apoptotic proteins individually
might be a promising treatment strategy. What is only recently becoming abundantly
evident is the importance of interactions between these proteins in both normal and
cancer cells. Protein:protein interactions are complex and the interplay between multiple
proteins in these complexes and their consequences on cellular phenotype are active
areas of investigation. It is also important that when targeting these proteins to block
their interactions off-target toxicity in normal cells and tissues is not promoted.
Our studies with Sabutoclax and the combination of Sabutoclax and Minocycline
may demonstrate the importance of such interactions through the potent loss of Stat3
activation observed with this treatment. Though the effect of Stat3 activation on Mcl-1 is
clearly defined, the reverse situation is not. Why does targeting downstream proteins
like Mcl-1 lead to such potent upstream signaling changes? Research into the literature
on Stat3 regulation and potential feedback loops through Mcl-1 or Bcl-xL reveal very
little. Known interactions between the anti-apoptotic Bcl-2 proteins with proteins outside
of this family do not play any known role in Stat3 activation. However, due to the low
dose of Sabutoclax that is being used, we feel strongly that these signaling changes are
not reflective of off-target effects of the drug. Rather, we have hypothesized that
Sabutoclax may be interrupting a protein:protein interaction between Mcl-1 or one of the
other antiapoptotic proteins and a yet unidentified second protein. Our theory is that
disruption of this interaction may release this second protein, which we hypothesize to
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have either direct or indirect effects on Stat3 activation. Recent studies by Maurizio
Pellecchia’s group have provided evidence that may support this hypothesis (161).
Using Sabutoclax as competition, they screened a 12-residue phage display library for
peptides that bound Mcl-1, specifically the BH3 binding domain. Their studies resulted
in the identification of a novel Mcl-1 protein-binding motif and subsequently, novel
potential protein interaction partners that display this motif. This is significant, especially
for our studies, as it sheds light on previously unknown Mcl-1 binding partners. As we
have hypothesized that such an interaction may be mechanistically responsible for the
effects we have observed with Sabutoclax and Minocycline, this new information
provides a beneficial point from which to develop future studies.
In continuing efforts to develop new and better BH3 mimetics, understanding
potential mechanisms of resistance is critical. Resistance remains a significant problem
in cancer therapy in general, and understanding how it develops may be of great value
in designing approaches to circumvent this major barrier to cure. Considering that the
Bcl-2 family of anti-apoptotic proteins plays a critical role in cancer maintenance and
resistance, these proteins represent high-priority targets for the next generation of
combinatorial therapies for neoplastic diseases.
The development of novel targeted agents, however, is only as useful as the
model with which you can test them. Our studies characterizing the PMV mouse are
very exciting, as this strategy elevates the sophistication and utility of the KPC
transgenic mouse model by adding a non-invasive imaging component. This mouse will
soon be used in therapeutic studies that we hope will produce beneficial preclinical
data. Future studies will focus not only on using these mice for preclinical work, but
136

also on improving the model even more. To enhance further the value of the PMV
mouse we intend to create a transgenic mouse producing the human secreted
embryonic alkaline phosphatase (SEAP) protein selectively in cancerous pancreatic
tissue by regulation through a cancer-selective promoter, CCN1-Prom. Crossing
tCCN1-SEAP animals with PMV animals will produce compound ‘Pancreatic Biomarker
Metastasis View’ (PBMV) mice. This model would not only have a built-in imaging
system to non-invasively monitor tumor development and growth, but it would also have
a built-in biomarker detection system to support and confirm imaging analyses noninvasively. Early detection of tumors can be integral in managing the life of a patient
with cancer, but in most situations achieving this objective can be problematic. Although
imaging and other modalities have been used for this purpose for subsets of cancers,
developing a more direct approach would be of added benefit. The ability to detect
cancer biomarkers in a patient’s blood sample represents a valuable contribution to
cancer detection. Unfortunately, there has been limited success to date clinically due to
sensitivity and specificity issues related to a given biomarker.
SEAP transgenic mice have been previously engineered in which SEAP
expression is under the control of an organ-specific promoter (162) and adenoviruses
expressing SEAP under the control of cancer-specific promoters have been shown to
be functional both in vitro and in vivo (163,164). However, a transgenic animal that
expresses SEAP under the control of a cancer-specific promoter is a novel strategy that
would further enhance the utility of our PMV mouse. Depending on the sensitivity of this
system, it may even allow us to detect tumor initiation earlier than with BLI. This dualmonitoring compound transgenic model would be unique and would significantly
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enhance a variety of chemoprevention and therapeutic studies in pancreatic cancer
transgenic as well as in other cancer transgenic mouse models.
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